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Abstract 
 The challenges facing the health system in South Africa are likely to impact on life-long 
adherence for patients in the context of the rollout of ART. Smaller ART programs have been able 
to demonstrate good adherence rates, but the question remains if this can be achieved by large 
public sector ART programs.  Most adherence researchers share the basic understanding that 
patients are adherent when they take their medications as prescribed by the health provider. An 
approach to adherence that combines both clinical and social knowledge—a biosocial approach— 
is likely to move us to a better understanding of adherence and how to improve adherence to ART.  
This study on social support and ART adherence aims to gather and document information that 
could be used to improve services and program strategies for strengthening and maintaining 
adherence at ART rollout sites in Gauteng.  The two study sites Carletonville Hospital and Zola 
Clinic were chosen randomly from all second-generation rollout sites in the Province. Data were 
collected from a total of 359 respondents, 164 in Carletonville and 195 in Zola. The response rate 
was 98.3%.   
 
The results showed that the majority of the respondents were female (72.1%) and about 
44.9% were within the age group 30-39 years. In terms of educational attainment, most 
respondents (70.1%) had received secondary education and 2.5% had not attended school. Based 
on assets quintiles scores of 1-5, with 5 being the highest score, about one-third of the respondents 
scored 1, and only 7% scored 5. Compared with Carletonville, respondents from Zola were more 
educated and better resourced. At the facilities, treatment preparation and support and adherence 
assessment procedures are routine features of the ART program and entail pre and post test 
counseling, group education and adherence counseling and serve as mechanisms for adherence 
support. This is enhanced by routine follow-up appointments where ART patients are provided 
information on side effects of ARVs, effectiveness of treatment, CD4 cell and viral load counts and 
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referral to services not provided at the facility. Additionally, support groups accessed by patients 
undertake a range of educational activities on staying healthy, viral load and CD4 cell counts and 
ARVs.   Although respondents were largely positive about their interactions with health providers 
and the support they provided, some expressed concern about health workers being too busy to 
address their problems, not treating patients with enough respect and sometimes patients leaving 
without receiving treatment because staff  were either absent or late or queues were too long.  
 
The HIV disclosure rate was high (95.5%). However, respondents were more likely to 
disclosure to a family member, but less likely to a friend, neighbor or religious leader. Self-
reported adherence and viral load adherence rates were high (97.6% and 76.6% respectively) but 
CD4 adherence was lower at 51.0%.  The study did not document a convincing association 
between social support and ART adherence. Only two variables (receiving food supplements and 
age groups) were significantly associated with CD4 and viral load adherence.    
 
Given the limitations of the study, a longitudinal study is needed in these sites to better 
understand the predictors of short and long-term adherence and to explore ways to better measure 
the relevance, content and quality of the social support services being utilized by ART patients at 
facility and community levels.  Interventions and policies are needed to respond to the concerns 
identified from the study regarding inadequate attention and respect by health providers, absence or 
lateness of doctors and pharmacists and challenges pertaining to access to food, income and 
disability grants.  
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CHAPTER ONE  
 
1.0: BACKGROUND  
 The study on social support and antiretroviral therapy (ART) adherence is part of a larger 
study coordinated and supervised by the Centre for Health Policy (CHP), University of 
Witswatersrand to investigate and understand the factors affecting adherence to anti-retroviral 
therapy (ART) in poor urban communities in South Africa. The study was conducted in 
Carletonville Hospital and Zola Clinic and complements the other arms of the CHP study, which 
examined: (i) the quality of patient and client interactions and loss to follow-up; (ii) organizational 
capacity to deliver ART services; and (iii) organizational factors affecting adherence.  The four 
study sites were Carletonville and Natalspruit Hospitals and Zola and Empilisweni Clinics in 
Gauteng Province.  
 
1.1: THE SOUTH AFRICA ART PROGRAM 
The South African Cabinet approved a plan for a national HIV/AIDS treatment rollout 
program in 2003 (1).  The goal of the plan was for at least one service delivery point in each 
district to be able to provide treatment in the first year, followed by the development of more 
treatment points. To meet requirements to provide ART, in addition to medical services, sites 
would have a ‘full range of community support services’ including counseling, adherence support, 
community mobilization, home and community based care and palliative care.  The Department of 
Health identified key challenges to implementing the treatment Operational Plan to include: 
strengthening existing programs that provide entry points to treatment (VCT, PMTCT, TB 
programs); building strong partnerships between health facilities and community support 
structures; and obtaining good patient information.  
 
 10
 Approximately 175, 000 of the 983,000 estimated by UNAIDS to be in need of treatment in South 
Africa were receiving ARVs by July 2006 through the public sector.  It is estimated that another 
100,000-110,000 people are on ARVs   through the private sector and so far ART services have 
been rolled-out in 273 sites, with an estimated 68.8% coverage. (2).   The number of ART 
accredited sites in Gauteng Province stands at 27, and rollout of treatment began in 2004. 
According to the National Department of Health, 55,580 adults and 6,301 children had accessed 
ART at the end of October, 2006.  
 
In order to improve coverage and strengthen the ART program, the treatment care and 
support priorities of the recently approved South Africa Strategic Plan (2007-11) include the 
following: a) ensuring uninterrupted supply of appropriate drugs; b) building the capacity of health 
professionals to provide comprehensive HIV and AIDS, STI and TB treatment and other related 
conditions and c) establishing a strong link between health facilities and community-based support 
programs.  
 
1.2: LITERATURE REVIEW 
1.2.1: Definition of social support and measurement of adherence 
Social support is defined in many ways, but the core principle relates to the ways and 
sources of support people going through difficult situations can access in order to cope. One 
definition describes three components of social support: emotional support which has to do with 
comforting through physical affection or expressing concern for wellbeing; guidance support 
which has to do with giving knowledge on how to do something or suggesting some helpful action; 
and tangible support which includes provision of material assistance such as housing, money, 
transportation and others. (3).  Another definition focuses on the sources of social support, 
describing it as the physical and emotional comfort given by family, friends and co-workers and 
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others as well as knowing that one is part of a community of people who love and care, and value 
and think well of others (4).  Family practitioners for example, see social support as a significant 
resource for individuals and family members encountering stress. There has, however, not been an 
adequate way to assess an individual's or a family's perception of the social support they are 
receiving. Definitions of social support should include two dimensions of social support: (a) the 
kinds of support available, such as emotional support; and (b) the sources of support, such as 
friends (5)   
 
The survival of people diagnosed with HIV dramatically improves with access to ARVs. 
ARVs suppress viral replication and prevent further destruction of the cellular immune system 
thereby allowing increase in CD4+ cells, which improves immunological response to opportunistic 
infections. Adherence is usually described in terms of the proportion of doses of prescribed ARVs 
taken. Cut-off points often used are: 80-90% of all doses taken (adherence) and 60-70% (poor 
adherence) and under 60% (non-adherence) (6).  But, the consensus is that in order to achieve 
undetectable viral load, and prevent the development of drug resistance, a person needs to take at 
least 95% of the prescribed drug doses. However, across a number of studies, results show that 
high rates of adherence do not always correlate with undetectable viral load (7, 8). This is partly a 
reflection of the way adherence is measured. There is no gold standard as to how adherence should 
be measured. Often patients are asked to report how many doses they have missed in last day, or 
two days or two weeks.  Patient feedback may be influenced by poor recall, interest in providing a 
socially acceptable answer, or the quality of the interview. Alternatively CD4 counts and viral load 
measures may be used as a proxy measure of adherence. 
 
In clinical trial conditions data from the USA suggest that 70-80% of patients are fully 
adherent to ART (9).  In the African context, a case study from the Khayelitsha Medecins sans 
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Frontieres (MSF) project reported high levels of adherence resulting from combining simplified 
regimens with low pill burden and a comprehensive patient support program. A total of 89% of 73 
respondents in 2003 reported adherence greater than 95% at three months on treatment. (10). In 
Uganda, self-reported adherence among 304 ART patients in Kampala was assessed to be 
comparable to levels in resource-rich settings (11). High adherence levels were also observed in a 
recent study from Uganda (12) in which participants received individual and group sessions on 
HIV prevention, care and treatment, family members received education, clients had support from 
a “medicine companion” and health workers delivered medications at home. The proportion of 
pills used and daily doses taken was 98-99%. A quarterly follow-up showed that less than 0.7-2.6% 
of clients took less than 95% of their pills, and 3.3 to 11.1% took less than 95% of daily doses. In 
the fourth follow-up quarter, 96% of participants had a viral load of <1000copies/μl. Independent 
predictors of high viral load (>1000 copies/μl) were pill use less than 95%, and taking less than 
95% of the daily dose of medications.  Research indicates that missing more than 5-10% of doses 
leads to incomplete suppression of viral replication and declining CD4 cell count (13, 14).  
 
Despite challenges in measuring adherence, studies have shown a significant association 
between high levels of self-reported adherence and viral load count. For example, a South African 
study showed that among 700 patients investigated, over 95% of all doses had been taken on pill 
count returns, and 94% of the patients had viral suppression rates of less than 400 copies/ml (15).   
 
Loss to follow-up is another factor that impacts on the success of ART adherence.  A study 
conducted at the Helen Joseph Hospital analyzed data on 74 patients who had stopped attending the 
clinic. The results showed that 35% had died, 30% were still alive and the status of others was 
unknown. Of the patients who were living, the reasons for non-return to the clinic were: had moved 
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(43%), had side effects (19%), transport/financial problems (14%), employment factors (5%) and 
unknown reasons (19%) (16).   
 
1.2.2: Factors affecting adherence 
Currently, very different approaches and models are being adopted to promote ART 
adherence, but it is not clear if and how effective these are. A study in the USA, which examined 
barriers to positive adherence, showed that forgetfulness, social and physical environment, drug 
side effects and patient knowledge played a role. Factors associated with good adherence included 
use of mechanical devices, commitment, social and professional support and health beliefs (17). In 
comparison, recently reported results of a workplace ART program in South Africa (18) showed 
that being away from home, forgetfulness and feeling worse were commonly cited reasons for 
missing tablets. The study also examined reasons patients declined to initiate ARVs. The most 
common reasons for refusal were not being convinced of the benefits of treatment, and inability to 
accept HIV diagnosis.  
 
In general, it is commonly acknowledged that multi-faceted interventions, including social 
support are needed for good chronic disease care outcomes, yet research on ART adherence has 
tended to focus on micro factors limiting themselves to experimental control such as educational 
strategies, scheduling accommodations to the regimen, and various forms of reminders, which 
achieve only modest results (19, 20).  
 
  Adequate attention has not been paid to research required to understand how social factors 
influence adherence. It is however, known that several sociological and psychological factors 
influence adherence of patients to treatment (21), and these have been summarized to include:   
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- Scheduling demands and accommodations. Scheduling demands are challenges which relate to 
work, daily routine and mealtime dosing, and scheduling accommodations are the steps taken to 
deal with these challenges e.g. pill-boxes, use of a timer, fitting work routine to fit daily medication 
schedule.  
- Cognitive demands/accommodations: Cognitive demands refer to patient difficulties in 
concentrating, forgetfulness and inadequate information. Cognitive accommodations refer to 
accurate understanding of purpose of ART, feedback on adherence achieved, and patient education.   
- Mental health:  Refers to depression, hopelessness, anxiety, psychiatric morbidity, and avoidance 
of positive attitudes about the future, long term plans and goals, active-behavioral coping, and 
stable mental health all demonstrated consistent relationships with adherence. 
- Treatment and medication attitudes: Fear and skepticism of the drug regimen, mistrust and myths 
regarding treatment, trust in drug efficacy and positive expectations of their effect are consistently 
associated with adherence. 
- Social climate:  Social support, confidentiality fears and fear of public exposure are either 
positively or negatively associated with adherence. 
- Provider support:  This includes the extent of support from the care provider, and the patient’s 
perception of the provider’s degree of caring. 
 
 
 1.3:  STUDY JUSTIFICATION  
The challenges facing the health system in South Africa are likely to impact on life-long 
adherence for patients in the context of the rollout of ART. Smaller treatment programs have been 
able to demonstrate good adherence rates, but the question remains if this can be achieved outside 
carefully monitored sites such as the well-resourced MSF program in Khayelitsha, which has 
placed 2,000 people on ART since inception in 2001.  By the end of 2004, 225 patients had been 
on treatment for more than two years. A study examining adherence in this group showed high 
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adherence levels, with 90% of the clients reporting that they were adherent after 12 months. The 
study concluded that among other things, social support from family, friends, support groups, 
treatment literacy as well as disclosure are critical for adherence. It found that men who were likely 
to be non-adherent were unmarried or lived alone, had poor social support, were reluctant to 
disclose and consumed alcohol (22). Similarly, a smaller study conducted at a government facility, 
the Helen Joseph Hospital in Johannesburg to determine the factors influencing adherence showed 
that over 92% of 184 patients on ART interviewed were adherent (less than 2 doses missed in the 
prior 3 weeks). Poor patient knowledge, negative perceptions of the provider-patient relationship, 
socio-economic barriers such as transport and lack of family support were associated with low 
adherence (23).  However, more information is required to understand what is going on in the 
public sector ART programs in terms of social support and adherence given the goal to put 1.4 
million people on treatment by the end of the decade.  
  
 Most adherence researchers share the basic understanding that patients are adherent when 
they take their medications as prescribed by the health provider. An emphasis on this limited 
approach impairs our understanding of adherence as a complex process embedded in the clinical 
and social course of AIDS.  An approach to adherence that combines both clinical and social 
knowledge—a biosocial approach—is likely to move us to a better understanding of adherence and 
how to improve adherence to ART.  The biosocial approach enables an understanding of how 
adherence changes over time, and the reasons for non-adherence.  Berkman et. al. (24) developed a 
conceptual model to show how social factors impact on health (See Figure 1). These include macro 
factors – socio- structural conditions which influence the extent, shape and nature of social 
networks (mezzo factors), which create the opportunity for micro factors, largely psychosocial 
mechanisms to operate and impact on health through different pathways.  There are four primary 
pathways through which micro factors impact upon health. These are through: social support, 
social influence, social engagement and attachment, and access to resources and materials.  
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 This study will focus on aspects of psychosocial mechanisms (downstream factors) such as 
social support, social influences, and access to resources and materials, which could affect 
adherence to ARVs. It will assess how support from health providers, family and friends as well as 
HIV and ARV related knowledge, educational level and HIV disclosure relate to reported 
adherence levels and biological outcomes such as CD4 cell and viral load counts.  Aspects of the 
framework by Berkman et al relevant to the study are highlighted.    
  
          Figure 1: How Social Integration Affects Health (Berkman et al 2000) 
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1.4: RESEARCH HYPOTHESIS   
ART clients who receive social support that is sensitive, relevant, sustained and 
reinforced at different levels will be motivated to adhere to treatment and to remain in ART 
programs in the long-term. For this study, it is hypothesized that patients who have access 
to and participate in support group activities, receive support from health providers, family 
and friends, disclose their status and have high HIV, AIDS and ARV knowledge are likely 
to achieve high adherence levels.  
 
1.5: STUDY OBJECTIVES   
The study aims to gather and document information that could be used to improve 
services and program strategies for strengthening and maintaining ART adherence at two 
rollout sites in Gauteng.  The specific objectives are to: 
1. Determine what types of support services are available at facility and community levels 
for ART adherence in the sites of the study.  
2. Investigate what social support services patients are using and how these services are 
meeting their needs. 
3. Determine adherence levels among ART patients and examine the association between 
social support and adherence.   
 
1.6: ETHICAL APPROVAL  
The research protocol (Protocol Number M051101, 2005), and instruments for the 
study were submitted to the Committee for Research on Human Subjects (Medical), 
University of Witwatersrand in 2005.  Approval for the study was given after minor 
corrections were made to the protocol based on suggestions from the Committee.  See 
Appendix 1. 
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CHAPTER TWO 
 
2.0: METHODOLOGY  
Chapter two describes the methodology of the study including the study design, 
study sites and study population. It provides a brief outline of questionnaire development 
and pre-testing and describes some of the steps taken to obtain administrative approval to 
conduct the study and to gain access to the sites. Data management procedures and 
methods of analysis, the scope and limitations of the study and plan for dissemination of 
results are also discussed.    
 
2.1: STUDY DESIGN  
This is a cross-sectional descriptive study conducted in two randomly selected 
health facilities, a hospital and a community clinic in Gauteng Province.  The study 
comprised of both quantitative and qualitative components.  Exit interviews were 
conducted with ART patients, while in-depth interviews were conducted with key 
respondents involved with the ART program at the two sites.  The study was conducted 
over a two-month timeframe.  Data collection was first completed at the first site 
(Carletonville Hospital) before the second site, Zola Clinic was embarked upon. This 
approach made it easier to manage the logistics given the distance between the sites, and 
provided the opportunity for the research team to learn from the experience of the first site.      
 
2.2: STUDY SITES   
The two study sites, Carletonville Hospital and Zola Clinic were chosen randomly 
from all the second-generation rollout sites in the Province, which did not have the same 
magnitude of time and resources as were dedicated to the pioneer or champion rollout sites. 
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The Carletonville Hospital is a district hospital, while Zola Clinic is a community health 
center.  These two facilities are located in regions A and B in Gauteng Province.  The 
Carletonville Hospital started rolling-out ART in February 2004. At the time of the study, it 
had 377 patients still on the program, having enrolled 540 since inception. Daily services 
provided at the ART clinic include HIV testing, assessment of patients for ART, 
counseling, referral and follow-up appointments. About 50 patients are attended to each 
day. The ART clinic operates on Mondays, Tuesdays and Wednesdays and the Wellness 
Clinic on Monday to Friday. However, rollout services are available daily to accommodate 
patients who cannot attend on the designated days. The ART program team is headed by a 
Manager, and includes 1 doctor, 1 pharmacist, 2 professional nurses, 1 nursing assistant, 5 
lay counselors, 1 dietician, 1 social worker, 2 clerical and 3 support staff.  
 
At the Zola Clinic, the “Khululeka” Wellness/ART Clinic provides rollout services 
Monday to Thursday and wellness and follow-up services on Tuesdays and Thursdays. 
Zola Clinic started rolling-out ART in October 2004 and in total enrolled 1,001 with about 
885 patients still using services. The daily client load is about 200. The ART program has a 
multi disciplinary team comprising 1 doctor, 2 professional nurses, 2 auxiliary nurses, 2 
nursing assistants, 1 dietician, 7 lay counselors, 1 social worker, 1 pharmacist, 1 clerical 
staff and support staff.  At both sites, the Comprehensive Care Management and Treatment 
(CCMT) Manager, a registered nurse, heads the ART program.   
 
2.3:  STUDY POPULATIONS  
The respondents for the exit interview were HIV positive men and women who had 
been on ARVs for at least 3 months.  Other inclusion criteria were: aged 18 years and over, 
willing to take part in the study and available for interview. All respondents meeting the 
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inclusion criteria were interviewed during their routine visit to the ART/Wellness Clinic. A 
total of 164 and 195 patients were interviewed in Carletonville Hospital and Zola Clinic 
respectively. Management and health staff including the ART Program Managers, doctors, 
pharmacists, nurses and social workers were interviewed to collect qualitative data.  
 
2.4:  INSTRUMENT DEVELOPMENT   
A draft structured exit questionnaire was developed using questionnaires previously 
used to collect adherence data, or determined to be relevant to the study.  The questionnaire 
addressed some of the key domains identified for the CHP studies aimed to understand the 
factors affecting access to ART in poor urban communities in South Africa (See appendix 
2). After a number drafts were developed, the questionnaire was pretested with 8 
individuals receiving ARVs at different facilities in Gauteng. The questionnaire was 
modified after the pre-test, and a workshop held to train interviewers was used to further 
refine and finalize the questionnaire. A final pretest was conducted with ART patients at 
the study sites prior to data collection. Once the researchers were satisfied, an adequate 
number of the questionnaire was reproduced for field use (See appendix 3).   The 
unstructured, qualitative instruments used were developed and pre-tested by two members 
of the research team.  
 
2.5: DATA COLLECTION 
Permission to conduct the study was requested by the CHP and provided by the 
Provincial HIV/AIDS/STI/TB (HAST) Manager. The Provincial HAST Technical Adviser 
provided a letter of introduction to the ART Managers at the sites.  At each site, key 
documents—questionnaire, ethics approval, letters of request and introduction (See 
Appendix 4a and b) and the study protocol were submitted to the facility management and 
 22
the research discussed. A meeting was also held with the ART Program Manager and staff 
to acquaint them with the research and to streamline the process and logistics for data 
collection.  Seven interviewers were trained during a 2-day period to administer the 
questionnaire. Training activities included:  a review of the different sections of the 
questionnaire, translation of key terms, questions, information sheet and consent form into 
local languages, role play and other practical exercises.  Five of the 7 were selected to 
conduct interviews at the two sites, with one taking on the role of supervisor.    
 
In Carletonville, respondents were interviewed in June and in July 2006 in Zola. All 
patients attending the ART clinic during this period were provided with information about 
the research by interviewers and requested to take part in the study. Respondents were 
informed of their right to participate or not to take part in the study, including withdrawing 
from the interview if they chose to.  Those who met the inclusion criteria and agreed to 
participate were requested to complete the consent form after the research study and the 
consent process were explained to them. Data were collected on socio-demographic 
background, ART and HIV/AIDS knowledge, continuity of care, ART adherence, 
experience with ART services and social support. A total of 359 respondents were 
interviewed. The response rate was very high, only 6 people declined to take part in the 
study, giving a response rate of 98.3%.   Qualitative and quantitative data collection took 
place simultaneously.   Ms. N. Naidoo contacted key respondents to obtain their consent to 
participate and make interview appointments. To record feedback from the interviews, 
copious notes were taken, and later analyzed thematically.     
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2.6: DATA ANALYSIS 
 A data entry screen was created on EpiInfo and data from completed questionnaires 
were captured individually for the two sites. The data were then combined, and exported to 
STATA for analysis.  Statistical analysis was conducted on variables relating to 
respondents’ socio-demographic background, use of support services, ARV, HIV and 
AIDS knowledge and perceptions, interaction with health providers and adherence levels. 
Combined frequencies were obtained for variables of interest, and comparisons between 
respondents from the two sites were made to determine differences.   The data analysis plan 
is summarized in Appendix 5.   
 
 Chi square and p-values were used to determine the association between ART 
adherence and social support. Adherence was measured in three ways: using self-reported 
adherence, viral load and CD4 cell counts.  Self-reported adherence was based on a scale 
measuring: 100% adherence and more than 5% missed tablets. Viral load and CD4 cell 
count were obtained from patients’ records.   CD4 cell counts were categorized in two 
groups:  CD4≤200 cells/ml and >200 cells/ml, while viral load counts were grouped into: 
VL≤400 copies/ml and > 400 copies/ml to measure adherence and non-adherence 
respectively.  
 
 A record review form was designed to collect routine data from clients’ records. 
This included data on: date when ART was started; total number of visits scheduled; CD4 
and viral load counts and TB screening and treatment. See Appendix 6.              
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CHAPTER THREE 
 
 3.0: RESULTS  
The results section focuses on the three objectives of the study. The results 
framework covers the description of the types of support services available at facility and 
community levels to promote ART adherence as well as institutional support to promote 
adherence; results on how ART clients are using available support services and their 
perceptions of these services, and the levels of adherence to ART using three measures— 
self-reported adherence, viral load and CD4 cell counts and how these relate to social 
support (See Annex 7). Clinic records at Zola indicated that of the 1001 patients enrolled 
since the program started, 885 were still in the program giving a dropout rate of 11.6%. In 
Carletonville, of 540 that had enrolled, 377 were still on treatment, giving a dropout rate of 
30.1%. The dropout rate at Carletonville is about 2.5times higher than at Zola.  
 
3.1:  SOCIO-DEMOGRAPHIC PROFILE OF RESPONDENTS    
The socio-demographic profiles of respondents are described below.  These include, 
age, gender, educational level and economic status. The results were analyzed in two ways 
- aggregated for both sites, and disaggregated by site to compare differences.   
 
3.1.1  Age distribution  
Respondents’ ages were categorized into 4 groups: 20-29 years; 30-39 years; 40-49 years 
and over 50 years.  Respondents’ age distribution is shown in Figure 2. 
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Figure 2: Age Distribution of Respondents (n=354) 
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Combined, the results show that most of the respondents fell within 30-39 years (44.9%), 
followed by 40-49 years (30.2%). Respondents from Zola were slightly younger than those 
in Carletonville.  47.7% of Carletonville respondents were aged 30-39 compared with 
41.6% in the same age group in Zola. Slightly more respondents in Carletonville were in 
the age groups 40-49, and 50+ years, but these differences were not statistically significant.    
 
3.1.2 Gender distribution  
 The proportions of males and females in the study are shown in Figure 3 below. 
Considering the combined results, the vast majority of respondents were female (71.9%). 
Comparing sites, the proportions of females and males were about equal: females - 72.4% 
and 71.3%; and males - 27.6% vs. 27.7% in Carletonville and Zola respectively. Overall, 
females were approximately 2.5 times more than males.   Across age groups, females were 
2-8 times the proportion of males, with the highest difference seen in 20-29 year olds (8 
times); the magnitude of difference was least among 40-49 and 50+ (2 times). The age 
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group difference between females and males was significant (Chi2= 12.986, p 
value=0.005). See Figure 3b.  
 
Figure 3a: Proportions of Males and Females (n=359) 
Gender Distribution: Combined
27.9%
72.1%
Male Female
72.6% 71.8%
27.4%28.2%
0.0%
20.0%
40.0%
60.0%
80.0%
Female Male
Gender Distribution By Site
Carletonville Zola
 
 
Figure 3b: Distribution of Age Across Gender 
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3.1.3: Educational levels   
This was grouped into 5 main categories as follows: NS- no school; PS: primary school; 
SS: secondary school and TS: tertiary school. In total, 2.5% of respondents had no 
schooling at all compared with 97.5% who had had any schooling.  The combined results 
show that most respondents (70.1%) had received secondary education while only 1.7% 
had received tertiary education.  (See Figure 4). Examining the levels of education, 
respondents from Zola appeared to be more educated than those from Carletonville. 
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Comparing respondents who had attended only primary school at both sites, the proportions 
were 38.4% in Carletonville and 15.0% in Zola. The difference was more marked when 
secondary school attendees were compared - 57.9% in Carletonville and 80.4% in Zola.  
The difference in the level of education between the two sites was significant. (Chi2= 
27.849; p value = 0.000).  
 
Figure 4:  Educational Levels of Respondents   
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Carletonville: n=164 
Zola: n=194 
 
3.1.4 Assets quintiles   
Asset scores for each household were generated using principal component analysis across 
all study sites.  Quintiles were then used to group the households, with 5 being the highest 
and 1 the lowest score, ranking the economic status of respondents. This rating was based 
on scores derived from groupings of assets and resources accessible to or owned by 
respondents and their household such as TV, fridge, car, type of housing lived in and fuel 
used for cooking and heating. See Figure 5 for combined distribution of asset quintile 
scores. The combined results show that most respondents, 33% had a score of 1 and 27% 
had a score of 2, and only 7% had a score of 5.  
NS: no school, PS: primary 
 SS: secondary and TS: tertiary school 
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Figure 5: Assets Quintile Scores of Respondents (n=359) 
 
 
Site-specific results indicate that respondents from Zola had a higher ranking than their 
counterparts from Carletonville (See Table 1.). Approximately 10% of Carletonville 
respondents and 27% of Zola respondents had a ranking of 5. Slightly more than twice as 
many respondents in Carletonville compared with Zola have a ranking of 1. These 
differences are statistically significant. (Chi2=34.831; p value = 0.000).  Assets scores were 
similar across gender.  
 
Table 1: Assets Quintile Scores by Site (%) 
 1 2 3 4 5 Total 
Carletonville (n=164) 29.9 17.1 27.4 15.9 9.8 100%, 
Zola (n=195) 13.3 17.4 16.4 25.6 27.2 100% 
P value = 0.000 
 
3.1.5: Access to income and grants  
About three-quarters of respondents in Carletonville (78.0%) and over one-quarter in Zola 
(37.4 %) were receiving a disability grant at the time of the study. 57.1% of respondents in 
Carletonville and 46.7% in Zola who were not on a disability grant reported having applied 
for one. In total, only a small proportion of respondents, about 1%, were on a medical aid 
 
Assets Quintiles: Combined
33% 
27% 
20% 
13%
7%
1 2 3 4 5 
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scheme. The proportion of respondents receiving food supplement in Carletonville is about 
three times higher than in Zola. Combined, only about 15% of respondents reported earning 
income in the last 2 weeks. Of those who earned income in the last two weeks, 
Carletonville had 11.6% and Zola 18.5%. Significant differences were seen for the two 
sites for two variables – receiving disability grant and food supplement (See Table 2).  
 
Table 2: Percentage of Respondents Receiving Financial and Material Resources  
 Combined 
(n=359) 
Carletonville 
(n=164) 
Zola 
(n=195) 
P value 
 % % %  
Has disability grant 56.0 78.0 37.4 0.000 
Applied for grant 49.0 57.0 46.7 0.277 
Has medical aid 0.8 0.6 1.0 0.666 
Gets food supplement 5.9 9.2 3.1 0.015 
Earned income 15.3 11.6 18.5 0.072 
 
Of those who worked, 52.6% in Carletonville and 57.2% in Zola described 
themselves as employed fulltime, while 15.8% in Carletonville and 11.1% in Zola reported 
being self-employed. About the same proportion from both sites said that they were part-
time or causal workers (see Table 3).    
 
   Table 3: Description of Employment Status (%)  
 Carletonville 
n= 19 
Zola 
n=35 
 Fulltime 52.6 57.2 
Self employed 15.8 11.4 
Part-time 31.6 31.4 
Total %  100 100 
P value =0.893 
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Although the proportions are small, seven times as many respondents in Zola 
reported that people at home often go hungry compared to Carletonville and nearly twice as 
many respondents in Carletonville compared to Zola said that household members rarely 
go hungry.   These differences are statistically significant – Chi2=12.88, p value 0.012.  
(See Table 4). These results suggest that respondents in Zola are more likely to have 
problems meeting their nutritional needs despite reporting earning an income and having 
higher assets quintile scores compared to Carletonville.  
                
Table 4: Proportions of Hungry Household Members (n=359) 
 Carletonville 
(n=195) 
% 
Zola  
(n=1640) 
% 
Often 1.2 7.7 
Sometimes 46.3 50.3 
Rarely 7.9 4.1 
Never 44.5 37.9 
Chi2 = 12.883; p value =0.012 
 
3.2: SUPPORT SERVICES AVAILABLE AT FACILITY AND COMMUNITY LEVELS    
A detailed description of the results pertaining to the types of support services at 
facility and community levels reported by respondents and health care providers is 
provided in this section. The results were derived from data collected through in-depth 
interviews with key respondents at the two sites, observations and exit interviews with 
ART patients.  
 
3.2.1: Facility and NGO support  
Using data from in-depth interviews and observations made during data collection, 
available facility and community-based support services were assessed. The results show 
that treatment preparation and support and adherence assessment procedures are routine 
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features of the ART program in Carletonville and Zola. However, there are some variations 
in their implementation. In both sites, treatment preparation entails pre and post test 
counseling, group education and adherence counseling, which serve as mechanisms for 
support. Home visits are conducted by the social worker in Zola, but not in Carletonville 
because it lacks the capacity to engage in this service. Home visits are used to assess 
patients’ social background to determine if there are any barriers to adherence. Treatment 
support also includes follow-up appointments, supply of pill-box (Carletonville only), 
tick/diary sheet and facilitation to access support group services. At Zola, the Clinic is run 
with the participation of a Clinic Community Committee, which addresses community and 
social issues affecting ART services.    
 
In Carletonville, NGOs and home-based care organizations such as the Kokosi and 
Carletonville Home Based Care Organizations provide support for HIV positive people.  
Also, the VCT unit runs a support group on Tuesdays, but it is unclear why ART patients 
tend not to use this service that is located on a different floor from the ART clinic. The 
program manager reported that while patients are not required to nominate a treatment 
buddy, peer support has developed spontaneously among them.  ART patients support one 
another, and often patients will notify the staff if a patient does not attend the clinic. Zola 
ART clients and affected families have access to support groups organized by the Red 
Cross and Hopeworldwide. In addition, ECHO provides both clinical and support services, 
operating a children’s VCT service once a week.   
 
Lay counselors prepare patients for treatment, assist with on-going adherence 
counseling and provide support to patients who are experiencing problems with their 
medication. Social workers also provide support to patients by assisting them with 
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accessing disability grant, phoning patients who do not show up for their appointment and 
helping to address family problems reported to them. Nutritional support is usually in the 
form of the provision of E/PAP (a high protein supplement) to patients who are 
underweight. Advice on the right type of food to eat is given to patients by the 
nutritionist/dietician.   
 
To assess adherence, patients are required to report treatment compliance. In 
Carletonville a 3-4 day recall period is used. Zola uses a 14-day recall period to assess self-
reported adherence.  A monthly follow-up visit to collect medication and to conduct pill 
count is required. Viral load and CD4 cell counts are carried out at both sites every six 
months.  These measures are all used to assess adherence to medication, clinical outcomes 
and compliance with clinic attendance.  
 
3.2.2: Information, education and communication  
Respondents appeared to be exposed to information and education from two sources: a) 
from health facilities and providers and b) from support groups. In both facilities it was 
observed that there were several educational materials displayed in visible and accessible 
areas such as the laboratory, corridors, and television and consultation rooms.  These 
materials included charts depicting different ARVs by color, size and name and samples of 
ARV pills. Also, written information and pamphlets translated into local languages were 
available in Zola. As part of the preparation for treatment and during routine visit and 
assessment, patients are given a wide range of information including: side effects of ARVs, 
effectiveness of treatment, CD4 cell count, viral load count and information on where to 
obtain services not provided at the facility. Support groups conduct a range of educational 
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activities such as: advice and information on staying healthy, viral load and CD4 cell count 
and ARV education.   
 
Overall, respondents’ knowledge and perceptions on HIV and ARVs are 
impressive. These relate to respondents’ responses to questions pertaining to: transmission 
of HIV when on ARVs, use of ARVs when one gains weight or has no opportunistic 
infections and having unprotected sex while on ARVs. Compared by sites, the differences 
are statistically significant for all the variables examined. (See Table 5). Respondents in 
Zola have higher knowledge levels and better perceptions compared with those in 
Carletonville. Also, combined, just over half of the respondents (55.4%) said they could 
name the drugs they take and by site the proportions were 30.1% in Carletonville and 
69.9% in Zola (Chi2=43.403, p value=0.000).    
 
Table 5: Levels of ARV Knowledge and Perceptions 
True Combined 
(n=359) 
% 
Carletonville
(n=164) 
% 
Zola 
(n=195) 
% 
P value 
People on ARVs can transmit HIV 89.1 79.9 96.9 0.000 
Can stop ARVs after weight gain 2.0 4.3 0.0 0.003 
Can stop ARVs when no longer 
have OIs 
2.2 4.3 0.5 0.035 
ARVs cure AIDS 3.1 5.5 1.0 0.017 
Can stop ARVs after some years 1.7 3.1 0.5 0.008 
Missing a few tabs is ok  1.7 3.1 0.5 0.051 
Unprotected sex safe if on ARVs is 
safe 
1.4 3.1 0.0 0.001 
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3.3: USE OF SOCIAL SUPPORT SERVICES AND ENABLING  ADHERENCE 
FACTORS    
The study examined levels and preferences around disclosure and how respondents 
were accessing and utilizing available support services to facilitate adherence to treatment. 
The results are presented below.  
 
3.3.1: HIV and AIDS disclosure  
The combined disclosure rate (to anyone other than a health worker) was high - 95.5%.  
Disclosure rates are significantly higher for Zola, 99.0% compared with Carletonville, 
91.5% (Chi2=11.801, p value=0.001). Overall disclosure rates for males and females were 
similar, 94.9% and 95.6% respectively. When whom respondents had disclosed to is 
considered, they were less likely to have disclosed to neighbors and religious leaders, but 
more likely to have told a family member or friend.  Comparing Carletonville and Zola, 
there was a significant difference between the two sites regarding disclosure to family 
member (85.4% vs. 96.9%, Chi2 sq= 15.536, p value= 0.000), disclosure to a friend (47.6% 
vs. 60.5%, Chi2=9.213, p value=0.010), disclosure to neighbor (23.8% vs. 38.0%, Chi2 
sq=11.028, p value = 0.004) and disclosure to a religious leader (35.4% vs. 30.8%, 
Chi2=5.749, p value=0.055).  (See Table-6).  Of the 74% of respondents who reported 
having a partner, 70% of them said they had disclosed to their partner.   
  
Table 6: HIV Disclosure   
Disclosed to:  Combined 
(n=359) 
Carletonville 
(n=164) 
Zola 
(n=195) 
P value 
Family member 91.6 85.4 96.9 0.000 
Friend 54.6 47.6 60.5 0.010 
Neighbor 31.5 23.8 38.0 0.004 
Religious leader 32.9 35.4 30.8 0.056 
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On why they would keep their status a secret, respondents gave a wide range of 
reasons.  Combined, the most prevalent reasons were fear of violence (62.4%), lack of trust 
in people (78.0%), fear of being denied help (77.4%), fear of stigmatization (74.4%), fear 
of gossip (77.4%), and fear that the community will know (76.3%). No significant 
difference was observed when findings were disaggregated by gender in terms of whom 
they had disclosed to.  However, 8.4% of males and 4.8% of females reported that they had 
not disclosed to a family member.  A significant difference was seen between the two sites 
with respect to: fear of family rejection (29.9% vs. 10.8%, Chi2 20.722, p= value 0.000); 
fear of rejection by friends (51.8% vs. 38.5%, Chi2=6.443, p value =0.011); and fear of 
explaining to partner (38.1% vs. 26.2%, Chi2= 5.646; p value = 0.016). For these variables, 
respondents from Carletonville were more likely to have expressed fear than those from 
Zola.  (See Table 7).  
 
 Table 7: Reasons for Non-disclosure 
Reasons  Combined 
(n=359) 
% 
Carletonville 
(n=164) 
% 
Zola 
(n=195) 
% 
P Value 
Family rejection 19.5 29.9 10.8 0.000 
Rejection by friends 44.6 51.8 38.5 0.011 
Fear of violence 62.4 67.7 58.0 0.058 
Don’t trust people 78.0 79.3 76.2 0.447 
Will not get help 77.4 79.2 75.9 0.593 
Stigmatization fear 74.4 78.7 70.8 0.088 
Fear of gossip 77.4 81.1 74.4 0.128 
Fear Com. will know 76.3 79.9 73.3 0.146 
Fear explaining to 
partner 
31.6 38.1 
 
26.2 0.016 
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3.3.2: Reported use of support group services  
In total, only 12.6% of the respondents reported being a member of a support group. There 
was no significant difference between males and females and between sites in terms of 
support group membership. Combined, 11.8% of females and 14.3% of males belonged a 
support group. By site, support group membership was 12.8% in Carletonville and 12.5% 
in Zola. With respect to support group activities, most respondents participated on a weekly 
basis, 85.7% in Carletonville and 66.7% in Zola (See Table 9).   
 
Table 8: Participation in Support Group Activities (n=45) 
Sites Weekly % Monthly % Occasionally % Total % 
Carletonville (n=18) 85.7 4.8 9.5 100 
Zola (n=16) 66.7 8.3 25.0 100 
 
 The most frequently mentioned support group services utilized were: advice on 
healthy living, ARV information, treatment buddies, individual counselling and income 
generation activities. Facilitation in collecting medicines and food assistance were 
mentioned by only about half of the respondents who belonged to a support group. The 
results were generally comparable across the sites for most of the variables, but non-
significant differences were seen for some variables e.g.: treatment buddies, home visits, 
food and IGA. (See Table 9).   
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Table 9: Use of Support Group Services (n=45) 
% Combined 
(n=45) 
Carletonville 
(n=21) 
Zola 
(n=24) 
P Value 
Healthy living advice  93.5 95.2 91.7 0.632 
ARV Info  93.5 95.2 91.7 0.632 
Treatment buddies 93.5 100.0 87.5 0.094 
Help collect medicines 55.6 57.1 54.2 0.841 
Home Visit 75.6 81.0 70.3 0.431 
Food 60.0 47.6 70.8 0.113 
IGA 82.2 76.2 87.5 0.322 
Individual counselling  91.1 90.5 87.5 0.889 
 
 
3.3.3: Health provider support and interactions 
 Respondents reported on various types of support from and interactions with health 
providers. These were: being able to discuss with health workers in private, receiving full 
information on treatment, feedback on whether or not the treatment was working and 
communicating on sensitive issues such as disclosing if they missed taking tablets.  
Respondents’ perspectives on whether they were treated with respect, cared for, or referred 
to other facilities to receive services not provided in their own facility were also explored.   
 
The vast majority of respondents (79.4%) reported that they were able to 
communicate with their health provider in private.  There was a significant difference 
(Chi2 =19.373, p value=0.000) when both sites were compared. 89.6% of respondents in 
Carletonville compared with 70.8% in Zola reported ability to discuss with their provider in 
private.  However, 55 (69.6%) of the 79 respondents who could not discuss in private said 
that they were not bothered by this situation, a possible reflection of the high level of trust 
which the patients have in the providers. 32.0% of the respondents said that health workers 
were too busy to discuss their problems. There was a significant difference between the two 
facilities; about twice the proportion of respondents in Zola reporting that health workers 
were too busy. (40.5% vs. 22.0%; Chi2= 15.377, p value= 0.004). 
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With respect to support received from health workers, only about 11.0% reported 
that health workers did not discuss fully with them how the treatment works and side 
effects. More respondents in Carletonville compared to Zola said that they did not receive 
adequate feedback on side effects of ARVs from health workers. (19.5% vs. 3.6%, Chi2= 
25.399, p value=0.000).  96.1% agreed with the statement that their health worker provided 
them feedback on whether on not their drugs were working. Also, 97.5% of respondents 
agreed that the health worker understood the difficulty in taking ARVs and provided 
assistance. No significant difference was observed when results from the two sites were 
compared. The vast majority of respondents, 94.4% said that they were assisted to obtain 
care elsewhere (See Table 10). 
 
Table 10: Level of Support Received from Health Workers (%) 
Agreed Combined 
n=359 
Carletonville 
n=164 
Zola 
n=195 
P value 
Able to discuss with HW in 
private 
79.4 89.6 70.8 0.000 
HW did not discuss treatment & 
ARV side effects fully 
10.9 19.5 3.6 0.000 
Difficulty telling HW if missed 
tablets 
44.6 39.6 48.7 0.084 
HW too busy to listen to problems 32.0 22.0 40.5 0.004 
HW provided support to take 
tablets  
97.5 97.6 97.4 0.666 
HW provided feedback on 
whether drugs were working 
96.1 94.5 97.4 0.438 
HWs do not treat patients with 
sufficient respect 
60.7 50.0 69.7 0.000 
Given help to obtain care 
elsewhere 
94.4 92.1 96.4 0.135 
HW cares about me 95.0 97.0 93.0 0.095 
Left without receiving help 17.6 3.7 29.2 0.000 
Queues are too long 89.7 87.8 91.3 0.290 
  
 The majority of patients (60.7%) said that staff did not treat patients with enough 
respect, and a significant difference was observed between the two sites (Chi2= 24542, p= 
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value 0.000). 50.0% of Carletonville compared with 69.7% of Zola respondents reporting 
that staff did not treat patients with sufficient respect.  Even though the majority of 
respondents reported this finding, they nonetheless felt that health staff cared for their 
patients. Overall, 95.0% said that the health workers they see cared for them. There was no 
significant difference between the two sites. 
 
Regarding satisfaction with services obtained, altogether 17.6% reported that they 
had left the hospital without receiving treatment since enrolling. Comparing the two sites, 
29.2% of Zola, and 3.7% of Carletonville respondents reported having left without 
treatment (Chi2= 40.551, p value = 0.000). The key reasons for not being attended to are 
listed in Table 11. They are absence or lateness of the pharmacist or doctor or long queues.  
 
    Table 11: Reasons for Not Being Treated  
Reasons  Carletonville 
% 
n=6 
Zola % 
n=57 
Pharmacist absent/late  0.0 64.5 
Doctor absent/late 0.0 17.0 
Long queue 0.0 8.3 
No ARVs  0.0 3.4 
Staff were too busy 16.7 0.0 
Left to see another doctor  16.7 0.0 
Other reasons 66.7 7.0 
Total  100% 100% 
 
3.3.4: Support from family and friends  
The types and use of support services provided by friends and family members were 
assessed.  These included home visits, sending “sms” messages as reminder to take 
medication, providing food, transport money and emotional support. Combined, the 
majority of respondents (88.0%) reported receiving emotional support from friends and 
family members compared with 46.8% who received “sms” messages and 59.5% who were 
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visited. About three-quarters said that they receive food and transport money to attend their 
follow-up ART appointment.  The results were similar for the two sites, except that in 
Carletonville a significant proportion of respondents reported receiving transport money, 
77.4% vs. 67.5%, chi2=4.637, p value=0.031 compared to Zola.  (See Table 12)  
 
Table 12: Help Received from Family and Friends 
% Combined 
n=359 
Carletonville
n=164 
Zola 
n=195 
P value 
Visit home 59.5 60.4 58.3 0.684 
Send sms 46.8 46.3 47.2 0.874 
Give food 77.9 78.1 77.8 0.889 
Give transport money 72.1 77.4 67.5 0.031 
Give emotional support 88.0 87.2 88.7 0.658 
 
Respondents were asked to specify if the behavior of the people they related with 
was supportive, unsupportive, both supportive and unsupportive or not relevant. Pertaining 
to how supportive friends, family and colleagues were toward respondents, combined the 
results showed that supportive attitudes were more commonly expressed by family 
members (87.5%) than by friends (52.9%) and people they lived with (36.2%). Only 10.9% 
reported that their colleagues were supportive. With respect to the two sites significant 
differences were observed for family, friends and colleagues. See Table 13.  Of 
respondents who reported having a partner/spouse, in total 80% described their 
partner/spouse as supportive; by site, 91.1% in Carletonville and 73% in Zola reported that 
their partner/spouse was supportive.   
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Table 13: Support from Family, Friends and Colleagues (n=359) 
Supportive 
behaviour 
Combined 
n=359 
Carletonville 
n=164 
Zola 
n=195 
P value 
Family’s behaviour 87.5 82.3 91.8 0.017 
Friends’ behaviour 52.9 46.3 58.5 0.030 
Behaviour of people 36.2 39.6 33.3 0.086 
Colleagues behaviour 10.9 14.7 7.7 0.000 
 
3.3.5:  Disincentives to adherence 
Respondents were asked to state 3 possible reasons why people would not take their 
medication.  Some of the most common responses provided are summarized in Table 14. 
Although respondents were not directly asked why they would not take their own ARVs, it 
gives an indication of what factors could impede their ability to adhere to treatment.  In 
Carletonville, the most common reasons cited were: drinking alcohol, being out of town or 
visiting, being irresponsible, being sick, having wrong information or negative attitudes 
towards ARVs, forgetfulness, and feeling better. The reasons were similar for respondents 
from Zola, except that the lack of food was cited by nearly 2 times as many people and 
stigma reported 2.5 times more by respondents in Zola compared with Carletonville. 
 
Table 14: Reasons People Miss Taking ARVs    
 Carletonville 
n=164 
Zola 
n=195 
Alcohol 35.4 30.5 
Out of town, visit/late home 23.1 14.0 
Don’t care, irresponsible 16.5 5.2 
Sick/Ill 15.9 12.2 
Wrong / negative views on ARVs 14.6 17.6 
Forget 13.4 6.2 
Feel well/better 10.4 11.9 
Lack of food 7.9 13.0 
Shame/stigma 4.9 10.3 
Don’t believe in ARVs 4.3 4.1 
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With respect to monthly appointments, only 9.5% of respondents said that there was 
a month when they had missed their appointment. There was no significant difference 
between the two sites, although respondents in Zola reported a higher frequency of missed 
appointments compared to Carletonville (11.4% vs. 7.3%). The main reasons for missing a 
monthly appointment in Zola had to do with being sick and in Carletonville being away or 
lacking transport money.  (See Table 15). 
   
  Table 15:  Reasons for Skipping Monthly Appointment (%) 
Reasons Carletonville 
n=164 
Zola 
n=195 
Working 
 N=34 
Yes: 0. 0 
No: 100 
Yes: 13.6 
No: 86.4 
Sick  
N=32 
Yes: 0. 0 
No: 100 
Yes: 50.0 
No: 50.0 
Forgot  
N=32 
Yes: 25.0 
No: 75.0 
Yes: 10.0 
No: 90.0 
Was away  
N=32 
Yes: 33.3 
No: 66.7 
Yes: 15.0 
No: 85.0 
No transport money  
N=32 
Yes: 41.7 
No: 58.3 
Yes: 15.0 
No: 85.0 
Nobody to look after 
children N=32 
Yes: 0. 0 
No: 100 
Yes 5.0; 
No: 95.0 
Afraid of negative 
judgment N=32 
Yes: 0. 0 
No: 100 
Yes: 5.0 
No: 95.0 
Afraid of partner 
 N=32 
No relevant: 8.3 
No:  91.7 
Not relevant: 0.0 
No: 100.0 
 
 
3.4: ADHERENCE LEVELS AND ASSOCIATION WITH SOCIAL SUPPORT 
The main results under this section pertain to levels of adherence measured by self-
reported, viral load and CD4 adherence.  The association between ART adherence and 
social support indicators is analyzed and presented. To provide additional context, an 
analysis of when respondents were first diagnosed HIV positive and when they first started 
taking ARVs was also carried out and compared with adherence.     
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3.4.1:  Length of period of HIV diagnosis  
Over half (55.9%) of respondents were diagnosed 1-2 years prior to data collection. Only 
2.7% had been newly diagnosed - less than 1 year.  22.2% of the respondents had been 
diagnosed for 3-4 years, 11.6% for 5-6 years and 7.6% for more than 6 years prior to data 
collection.  See Table 16.  
 
Table 16: When First Diagnosed with HIV Infection  
Years < 1 year 
(%) 
1-2 years 
(%) 
 
3-4 years 
(%) 
5-6 years 
(%) 
> 6 years 
(%) 
Total 
(%) 
Combined 
n=329* 
9 (2.7) 184 (55.9) 73 (22.2) 38 (11.6) 25 (7.6) 100 
Carletonville 
n=144 
2 (1.3) 88  (61.2) 31 (21.5) 15 (10.4) 8  (5.6) 100 
Zola 
n=185 
7 (3.8) 96  (51.9) 42 (22.7) 23 (12.4) 17 (9.2) 100 
* data missing on 30 respondents 
 
3.4.2:  Length of time on treatment  
Respondents were categorized into two groups based on the number of months they had 
been on treatment. These groups were: a) on ARVs for 6 or less months and b) on ARVs 
for over 6 months. In Carletonville this was calculated by determining the number of 
months between when they first started ARVs and June 2006 when data was collected, and 
in Zola, July 2006 was used. Information on when respondents first started taking ARVs 
was available for 271 respondents. Combined, 65.7% of respondents had been on treatment 
for over 6 months. The results for the sites show that in Carletonville 73.0% of respondents 
had been on treatment for over 6 months and 27.0% for 6 months or less. In Zola 59.7% of 
respondents had been on treatment for 6 months and over, and 40.3% for less than 6 
months (See Table 17). There was a significant difference between the sites when length of 
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time on treatment was compared (Chi2 = 5.200, p value=0.023), a higher proportion of 
Zola patients were on treatment for 6 or less months. 
 
Table 17: Length of Time on Treatment (n=271)  
Treatment 
Months 
Combined 
(n=122) 
Carletonville 
(n=122) 
Zola 
(n=149) 
6months 34.3 27.0 40.3 
>6months 65.7 73.0 59.7 
Total % 100 100 100 
Chi2=5.200, p value=0.023 
 
3.4.3: Adherence levels 
 The frequencies of the three measures of adherence analyzed are listed in Table 18 and 
described below. They are I) self-reported adherence ii) viral load adherence and iii) CD4 
adherence.  
i) Self-reported adherence (SRAdh): Self-reported adherence was high at 97.5% for all 
respondents using 100% adherence in the last 3 days. Compared by site, proportions 
were nearly identical with 97.6% vs. 97.4% for Carletonville and Zola respectively.  
Only a total of 2.5% reported that they had missed more than 5% of their tablets in 
the last 3 days. The proportions for both sites were also nearly the same.    
ii) CD4 cell adherence (CD4Adh): CD4 adherence was determined by two values 
(CD4>200 cells/ml and CD4 ≤200 cells/ml. CD4>200 cells /ml indicates adherence. 
Combined, 51.0% of 286 respondents for which CD4 data were available achieved 
CD4 adherence. The level of CD4 adherence was higher in Carletonville compared to 
Zola (53.5% vs. 48.1%). This difference was not however significant.  Combined, 
49.0% did not achieve CD4 adherence. 
iii) Viral load count adherence (VLAdh):  This was based on two values, a VL count 
equal to or less than 400 copies/ml for adherence and over 400 copies/ml for non-
 45
adherence. Viral load suppression (undetectable) was achieved by 76.1% of all 
respondents.   The VL adherence levels for Carletonville and Zola were similar, with 
Carletonville slightly higher (77.6% vs. 74.4% respectively). Combined, 23.9% did 
not achieve VL adherence.  
 
  Table 18: Adherence Levels: SRAdh, CD4Adh and VLAdh  
 100% adherence  
in last 3 days 
Missed more than 5%  
in last 3 days 
SRAdh   
Carletonville 
(n=164) 
97.6 2.4 
Zola (n=192) 97.4 2.6 
Combined  97.5 2.5 
 CD4 >200 cells/ml CD4 ≤200 cells/ml 
CD4Adh    
Carletonville 
(n=155) 
53.5 46.5 
Zola (n=131) 48.1 51.9 
Combined 
(n=286) 
51.0 49.0 
 VL≤400 copies/ml VL>400 copies/ml 
VLAdh   
Carletonville 
(n=143) 
77.6 22.4 
Zola  
(n=121) 
74.4 25.6 
Combined 
(n=264) 
76.1 23.9 
 
An analysis of VLAdh against CD4Adh showed a significant association as would 
be expected. See Table 19. The results indicate that 90.8% of respondents who achieved 
CD4Adh also achieved VLAdh, while only 9.2% of those who achieved CD4Adh did not 
achieved VLAdh.  Additionally, 63.5% of respondents whose CD4 cell count was 200 or 
less achieved VLAdh and 36.5% of those who did not achieve VLAdh also did not achieve 
CD4Adh. No significant association was seen when CD4Adh and VLAdh were tabulated 
against SRAdh.  This result of a strong correlation between CD4Adh and VLAdh, but of no 
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correlation between CD4Adh, VLAdh and SRAdh is of interest, but difficult to explain. It 
may be related to incomplete CD4 and VL count data or the fact that about one-third of the 
patients had been on ARVs for six months or less.    
 
Table 19: VL Adherence vs. CD4 Adherence (n=245) 
 VL≤400 
copies/ml
VL>400 
copies/ml 
Total  % 
CD4 >200 
cells/ml 
90.8 9.2 100 
CD4 ≤200 
cells/ml 
63.5 36.5 100 
Chi2=27.0996, P value=0.000 
 
3.4.4: Correlation between adherence and social support  
Social support and contextual variables were analyzed against adherence measures to 
determine correlation. Because SRAdh was very high, this measure does not constitute a 
suitable measure to determine association. Ideally, it would be useful to compare a number 
of social support indicators against those who reported 95% and over adherence and those 
who reported less than 95%. However, there were only 9 respondents in the latter group.  
Therefore, VLAdh and CD4Adh measures were used to explore associations between 
adherence, social support and contextual variables.  
  
a). Length of period on treatment and adherence:  Length of period on treatment was 
stratified into 2 groups – longer than 6 months and 6 or less months. When results were 
compared for adherence levels between these 2 groups for the 216 respondents for which 
data was available on both CD4 count and date when treatment was first started, it was 
found that 65.3% of those on treatment for over 6 months achieved CD4Adh .  The 
proportion of those on treatment for 6 months or less who had achieved adherence was 
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lower (43.1%). More respondents (56.9%) in this group were likely to have CD4 cell count 
that was less than 200.  As expected, CD4Adh compared with length of time on treatment 
showed a significant association (Chi2=9.482, p value=0.002). See Table 20. 
 
Table 20: Months on Treatment vs. CD4Adh (n=216) 
 CD4 >200(%) CD4≤200(%) Total 
> 6 months 65.3 34.7 100 
≤6 months 43.1 56.9 100 
P value=0.002 
 
In contrast, when VLAdh was compared with length of time on treatment no 
significant association was seen. The proportions between the two categories (6 months or 
less and over 6 months) were about the same - 76.6% and 75.6% respectively, See Table 21 
 
Table 21: Months on Treatment vs. VLAdh (n=201)  
 VL≤400 copies/ml VL>400 
copies/ml
Total % 
> 6 months 77.6 22.4 100 
≤ 6 months 75.4 24.6 100 
Chi2=0.1232, p value=0.726 
 
b).   Adherence by socio-economic status:  Three variables were used to assess correlation 
between adherence and socio-economic status of respondents. These were age group, 
educational level, and assets quintiles.  Considering age group, a significant association 
was seen with VLAdh (Chi2=9.7696, p value=0.012), but not with CD4Adh.  The 
proportion of respondents who achieved CD4Adh and those who did not were split nearly 
equally among respondents aged 20-29, 30-39 and 40-49. VLAdh on the other hand 
showed a different pattern of distribution when the age groups were compared.  See Tables 
22 and 23.     
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Table 22: VL Adherence vs. Age Groups (n=259) 
 VL≤400 
copies/ml 
(%) 
VL>400 
copies/ml 
(%)
Total % 
20-29 74.5 25.3 100 
30-39 69.1 30.9 100 
40-49 81.0 19.1 100 
50+ 100 0.00 100 
P value=0.012 
 
 
 
Table 23: CD4 Adherence vs. Age Groups (n=286) 
 CD4 >200 
cells/ml 
CD4 ≤200 
cells/ml 
Total % 
20-29 50.0 50.0 100 
30-39 49.4 50.6 100 
40-49 51.3 48.7 100 
50+ 75.0 25.0 100 
Chi2= 1.0165, P value=0.797 
 
When VLAdh and CD4Adh were compared with educational levels, no significant 
association was observed.  A similar observation was made when assets quintile scores and 
CD4Adh and VLAdh were compared.  However, with regard to assets, although no 
significant association was seen, respondents with an assets quintile score of 5 were nearly 
two times more likely to have a CD4 cell count over 200 (60.8% vs. 39.2%).  The 
proportions of respondents with assets quintiles 1-4 who were CD4 adherent and non 
adherent were fairly similar across these quintiles. See Table 24.   Viral load adherence 
compared across assets quintile scores showed that proportions of respondents who 
achieved VLAdh were between 3-5 times those who did not across the 5 scores. These 
differences were not significant. Respondents with a score of 5 also had the highest VLAdh 
level. See Table 25.  
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Table 24: CD4 Adherence vs. Assets Quintiles Scores (n=286) 
Assets Quintile 
Scores 
CD4 >200 
cells/ml 
CD4 ≤200 
cells/ml 
Total % 
1 43.3 56.7 100 
2 46.9 53.1 100 
3 56.1 43.9 100 
4 49.1 50.9 100 
5 60.8 39.2 100 
P=0.327 
 
Table 25: Viral Load Adherence vs. Assets Quintiles Scores (n=264) 
Assets Quintile 
Scores 
VL≤400 
copies/ml 
(%) 
VL>400 
copies/ml 
(%) 
Total % 
1 75.0 25.0 100 
2 76.2 23.8 100 
3 80.6 19.4 100 
4 72.6 27.5 100 
5 96.1 23.9 100 
P=0.885 
 
c) Adherence and social support: This was investigated by examining the relationship 
between social support and CD4Adh and VLAdh, using the following variables: support 
group membership, HIV disclosure, emotional support from family and friends, receiving 
food supplements, income in last two weeks and disability grants. The results are tabulated 
in Table 26. The main finding of interest is the significant association between CD4Adh 
and receiving food supplements.  
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Table 26: Adherence and Social Support  
 CD4 >200 
cells/ml 
CD4≤200 
cells/ml 
P value VL≤400 
copies/ml 
VL>400 
copies/ml 
P value 
Yes       
Support group 
member n=37 
59.0 41.0 0.287 70.3 23.9 0.367 
Disclosed HIV status 
n=251 
50.0 50.0 0.118 75.7 24.3 0.462 
Receive emotional 
support from family 
and friends n=235  
51.8 48.2 0.494 76.1 23.9 0.337 
Receive food 
supplement n=20 
80.0 20.0 0.007 90.0 10.0 0.130 
Income in last 2 
weeks n=37 
61.5 38.5 0.159 70.3 29.7 0.367 
Receive disability 
grant n=162 
49.7 50.3 0.580 77.8 22.2 0.430 
 
Of those who received food supplement (n=20), 80.0% achieved CD4Adh and 20% 
did not (Chi2=7.212, p value=0.007).   There was no significant correlation between 
VLAdh and receiving food supplement. Furthermore, no association was seen between 
CD4Adh and VLAdh and any other social support variable.   
 
d)   Adherence by ARV and HIV knowledge:  Respondents’ results for ARV and HIV 
knowledge and perceptions were tabulated against VLAdh and CD4Adh to determine 
correlation. No associations were observed for any of the 3 variables compared: ARVs cure 
AIDS; unprotected sex is safe when taking ARV; and one can stop ARVs after weight gain.   
See Table 27 for details of results. 
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Table 27:  ARV/HIV Knowledge and Adherence 
 CD4 >200 
cells/ml 
CD4≤200 
cells/ml 
P value VL≤400 
copies/ml
VL>400 
copies/ml 
P value 
Agreed % %  % %  
ARVs cure 
AIDS (n=286) 
90.0 10.0 0.074 70.0 30.0 0.154 
Unprotected sex 
safe when on 
ARV  
40.0 60.0 0.486 60.0 40.0 0.358 
Stop ARVs after 
weight gain  
57.1 42.9 0.896 71.4 28.6 0.434 
 
e) Adherence, interaction with and social support from health providers: Three main 
variables were used to assess any correlation between adherence and support provided by 
health workers. The variables addressed respondents’ perspectives on how helpful health 
workers were, and how positive their interactions were with them.  Correlation analysis 
showed no association between CD4Adh and VLAdh and health workers support for ART 
adherence with respect to assistance with taking ARVs, how busy they were to listen to 
their problems, and if respondents were referred elsewhere to seek care that could not be 
provided.  See Table 28.  
 
Table 28:  Health Worker Support and Adherence  
 CD4 
>200 
cells/ml 
CD4 
≤200 
cells/ml 
P value VL≤400 
copies/ml 
VL>400 
copies/ml 
P value 
Agreed  % %  % %  
HW assisted with 
problem of taking 
ARVs (n=264) 
50.7 49.3 0.531 76.1 23.9 0.710 
HW too busy to 
listen (n=264) 
48.4 51.7 0.299 75.3 24.7 0.952 
Referred for other 
care services 
(n=264) 
50.4 49.6 0.172 76.5 23.5 0.568 
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3.5: STUDY LIMITATIONS 
The study collected information from respondents at a point in time, focusing on their 
current experiences with adherence and their access to and use of social support services. It is 
therefore difficult to establish any causal relationship between exposure and outcome 
variables, which would require a different study design such as a prospective, longitudinal 
study or one with a well-established control group of non-adherent patients or patients who 
have dropped out of treatment. Also, because this is not a randomly selected study 
population, the results would largely apply to the study population and sites. Socio-
economic factors may also confound the results. Because the sample size is not large 
enough, it was not possible to adjust for possible confounders or to stratify respondents as 
much as one would like to. It was not within the scope of the study to investigate exposure 
to social support from the time patients were first diagnosed with HIV. This presents a 
problem as many patients may have received support, and were coping with their HIV 
status, and therefore needed little support to adhere when they started treatment.  
 
The study did not determine the quality of social support services or the frequency 
of use of the different support services by respondents.   Respondents reported accessing 
and receiving support from two levels – community and facility. The study did not 
investigate which support services were most beneficial to respondents, so it is difficult to 
draw any conclusions as to what source and type of social support services enhanced 
adherence among this study population.   Adherence measures included self-reported 
adherence, which is difficult to verify, and its reliability is a subject of continuing debate.  
The use of the more reliable adherence measures such as VL and CD4 counts to assess the 
association between adherence and social support was hampered by incomplete CD4 and 
VL data.  
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CHAPTER FOUR 
 
4.0: GENERAL DISCUSSION 
 In terms of socio-economic background, the study population consisted of a better 
resourced sub-population in Zola, with a higher level of education and economic status 
determined by assets quintile scores, and a poorer sub-population in Carletonville, that had 
lower educational levels and economic status. The study population was predominantly 
female and young adults mainly in the 30-39 age group. It is difficult to explain the 
preponderance of females accessing ART services (72.1% of the study population), except 
that generally women have greater access to HIV testing through routine screening 
services, particularly through antenatal clinics. But since there were only a few women at 
both sites who had accessed ART services through antenatal and the prevention of mother 
to child transmission (PMTCT) services, so this was unlikely to be a major source of 
referral for women to these ART clinics.  A similar finding in terms of the preponderance 
of women using ART services was seen in another South African study. In a retrospective 
study at the Helen Joseph Hospital in Johannesburg, about twice more women than men 
were initiated into the ART services at the Themba Lethu Clinic (25).  
 
 4.1: DISCUSSION OF RESULTS 
 Although several African studies on adherence have shown encouraging results 
with high levels of self-reported adherence found to be the norm  (26,27, 28), a recent 
review has shown that ART adherence and clinical outcomes vary widely across sub-
Sahara Africa, suggesting a mediocre to even poor adherence (29).  A study by Bekker and 
colleagues in South Africa (15) found a high level of self-reported adherence (95%), 
comparable to the results found in this study (97.6%).  However, the high level of self-
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reported adherence recorded for the study was not verified, additionally, incomplete 
adherence – not taking medication at the right time - was not investigated.  Interestingly, at 
both sites respondents gave similar reasons as to why people miss taking ARVs- mainly 
due to alcohol use/being drunk and being away from home. This could be a reflection of 
the respondents’ own experiences, suggesting that self-reported adherence levels obtained 
for the study might not in reality be as high. Furthermore, in Carletonville, a review of the 
hospital’s own records on patients’ self-reported adherence (3 or 4 day recall) showed that 
between 80-90% of respondents were adherent compared to 97.5% obtained in the study. 
The high self-reported adherence rate reported from this study should be viewed with 
caution because of the disparity with hospital records, among other considerations. 
 
 The viral load adherence was lower for this study than that reported among 700 
patients in the study by Bekker and colleagues in Khayelitsha: 76.6% versus 94% 
respectively.  From other studies, high self-reported adherence rates but low rates of viral 
load clearance were reported suggesting that self-reported adherence in Africa is proving to 
be an unreliable measure of adherence as it is elsewhere (7,8). Similarly, in this study 
approximately three-quarters of the respondents had undetectable viral load despite a very 
high level of self-reported adherence.  
   
A study by Michaels and colleagues (22) concluded that social support from family, 
friends, membership of support group, treatment literacy and disclosure were critical for 
adherence.  But, the use of social support services depends on awareness, availability, 
accessibility, and the level of stigma and disclosure of HIV status.   Disclosure of HIV 
status is perceived to be an important factor in enabling HIV positive individuals to seek 
and utilize services and to receive necessary support.  HIV disclosure rate for this 
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population was high (95.5%). A possible explanation could be the high level of support, 
especially emotional support received by respondents which could have fostered disclosure. 
Also, the fact that many of the respondents had been diagnosed with HIV for a long time, 
only a small proportion (2.7%) had been diagnosed for less than one year, may have given 
them ample time to come to terms with being infected, and to  take the decision to 
disclosure.  The high level of disclosure among respondents could also be an indication of 
their high degree of comfort and ability to cope with stigma and the trust they developed in 
the people they disclosed to. However, the results showed that respondents had preferences 
in terms of who they disclosed to, and that family members were a critical source of social 
support, providing particularly emotional support. Corroborating of this finding, it was 
observed that 87.5% of respondents also reported the behaviours of their family members 
to have been supportive.   
 
The support groups used by respondents provided support through identifying a 
“treatment buddy”, providing ARV education and counselling services, which were also 
offered by the facilities. It is therefore difficult to determine if the support groups provided 
any unique services to members. Generally, it appeared that support groups were not 
popular among these ART patients given that only a small proportion of them  (12.6%) 
participated in support group activities.  It is therefore unlikely that these ART patients 
depended much on support groups for ART adherence.  However, an informal but 
important source of support - peer support- evolved among these patients. This informal 
support system developed among patients who had their monthly appointments on the same 
date, and it seemed to be a key adherence support feature among patients in Carletonville. 
This system of support requires further enhancement, documentation and evaluation.    
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 Although the CCMT Managers reported several measures to support and assist 
ART patients, not all of them could be verified. For example, how well community 
outreach from Zola Clinic was working could not be ascertained. At Carletonville, the 
management staff reported that it was unable to conduct any community outreach. 
However, support in terms of providing educational materials, education, and counselling, 
routine assessment of adherence through pill count, self-reported adherence and CD4 cell 
and VL counts assessment appeared to be in place at the two sites.  With respect to social 
support from health workers, respondents had very positive views about the support they 
received from health workers, especially assistance with taking ARVs, discussion on side 
effects of  ARVs, feedback on whether ARVs were working and referral to obtain 
assistance and services that were not offered at their facility. The also perceived the 
providers to be very caring.   
 
 But, the effective delivery of these services could be compromised by the high 
workload of health workers;  nearly one-third of the respondents (32%) reported that health 
workers were too busy to pay adequate attention to them, and 89.7%  reported long queues. 
17.6% of respondents reported that they had left the clinic at least once without receiving 
treatment. These problems were more of a concern for patients in Zola, where a higher 
patient flow  (about 200/day) compared to Carletonville (about 50/day) seemed to be 
placing a lot of stress on the health workers, as well as available space and services.   
 
 There was a significant correlation between CD4Adh  and VLAdh. 90.8% of 
respondents who were CD4Adh were also VLAdh. This association was not seen when 
SRAdh was analyzed against CD4Adh and VLAdh. This result suggests that both CD4Adh 
and VLAdh provided reliable measures for adherence, but one could not probably say the 
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same for SRAdh. Overall 51.0% of the respondents achieved CD4Adh and 76.1% VLAdh, 
a rate comparable with the 79.6% to 59.3% rate reported by Laurent and colleagues in 
Senegal (30), but lower than the 94% viral load clearance rate reported by Bekker and 
colleagues in South Africa (22). 
  
 Correlation analysis comparing CD4Adh, VLAdh and social support variables, 
socio-economic indicators and length of time on treatment largely showed no significant 
association. This may be explained by the fact that VL counts were only available for 264 
(73.5%) of respondents and CD4 counts were available for 286 (79.7%) respondents. The 
proportions of respondents who were CD4 adherent and non-adherent were about the same 
(51% vs. 49% respectively).  This lower level of CD4 cell increase compared with a higher 
viral load clearance rate may be due to the fact that ARVs more readily and directly deplete 
HIV when initiated, and so fewer HIV particles become detectable in blood circulation. In 
the case of CD4, it is plausible that CD4 reconstitution takes longer, and lags behind VL 
clearance, however this needs to be substantiated by studies.  
 
 Significant correlations between CD4Adh and length of period on treatment 
(Chi2=9.482, p value=0.002) and CD4Adh and receiving food supplement (Chi2=7.212, p 
value=0.007) were seen. It can be said that valuable nutrients resulting from the use of  
supplements may have facilitated the reconstitution of the immune system, reflected by an 
increase in CD4 count. Thus, the association between access to food supplement and  
higher CD4 cell count was seen. Regarding CD4Adh and length of period on treatment, the 
results showed that 65.3% of respondents who were on treatment for more than 6 months 
had CD4 cell count of over 200 compared with 43.1% of those who were on treatment for 6 
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months or less. This is to be expected given that an increase in CD4 cell count progresses 
with time following initiation of ARVs.   
 
 The significant correlation (Chi2=9.7696, p value= 0.012) seen between age group 
of respondents and VLAdh is of interest. The age groups that showed higher proportions of 
VLAdh were 40-49 and 50+ years. A possible explanation is that older people are more 
stable, less mobile, less likely to abuse alcohol, and hence more able to adhere to treatment 
compared with younger people. This view is supported by the reasons provided by 
respondents for missing ARVs, which were mainly the use of alcohol, being away from 
home or not caring/being irresponsible.  Younger people may be more susceptible to these 
factors, which could affect their adherence to ARVs.   
    
4.2: CONCLUSIONS  
The study did not document a convincing association between social support and 
ART adherence.  One likely reason is that this population of HIV positive patients on 
ARVs may over represent those who cope better.  Also, the dropout rates for the sites were 
high. In Carletonville it was 30.1%, about 2.5 times that of Zola, which recorded 11.6%. It 
is possible that some of those who dropped out were less able to cope.  It was not possible 
to follow-up with these patients to determine how different they were in terms of their 
coping ability, access to and use of social support services and their adherence rate as the 
facilities maintained little or no contact with, or information on drop-outs. However, it 
could be postulated that the majority of the respondents had accessed adequate social 
support and were already coping with their HIV status prior to treatment initiation.  This 
however, could not be confirmed because it was not within the scope of the study to 
determine past exposure to and use of social support services.    
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Although CD4Adh and VLAdh were associated with some variables (access to food 
supplements, length of time on treatment and age groups), these could not be satisfactorily 
explained.    The high levels of SRAdh and adequate access to and use of social support 
services suggest that despite this lack of demonstrable association, these respondents were 
doing well particularly in accessing social support and they were largely satisfied with the 
support they were receiving from the ART clinic providers. This finding is of importance 
given concern about the ability of public sector ART programs to provide and facilitate 
support services which promote adherence. It, thus appears, that the support provided at the 
facility level – information, educational materials, training prior to starting treatment and 
counseling and community level support from families, friends and support groups were 
adequately meeting the main needs of the respondents and motivating them to adhere to 
ART. However, given the limitations of the study, it is not clear if the services being 
provided and utilized are all relevant, useful, of good quality, and sustainable.   
 
4.3: RECOMMENDATIONS 
Qualitative research is required to better determine how patients in these public 
sector facilities understand adherence and non-adherence to treatment and what factors they 
take into consideration in reporting self-adherence.  Additionally, it is necessary to unpack 
the meanings of social support in the context of ART, the key components of social 
support, and to understand which social support services are most beneficial for ART 
adherence. It is also important to explore practices pertaining to timely adherence in taking 
ARVs, as well as understanding of how the reasons reported for non-adherence apply to 
this population.   
Research that would lead to a better understanding of the behavioural factors that 
are necessary to maintain long-term, high level adherence and reasons why more women 
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than men are accessing treatment is also required. Based on a review of literature on ARV 
adherence and intervention studies, Goudge (31) made similar recommendations, including 
broadening the concept of social support/integration, interventions to assess which are the 
most effective approaches to improving adherence and determining the local contextual 
factors that are important and what works within that context.   
  
From the few African studies that reported longitudinal data on adherence, 
declining levels of adherence was noted over time.  For example, in Senegal, Laurent et al 
(30) noted that over 95% of their patients had adhered, exceeding 80% after one month on 
therapy. However, 18 months later, only 80% remained above this level. The proportion of 
patients with undetectable viral load correspondingly fell from 79.6% to 59.3%. Similarly, 
Akam (32) in Cameroon reported a mean self-reported adherence that was initially only 
68%, that declined further with time.  The ART programs in Carletonville and Zola are 
only about two years old, and only 65% of the patients had been on treatment for more than 
6 months. As seen from the studies reported from Senegal and Cameroon, adherence levels 
could decline with length of time on treatment resulting in a decline in VL clearance. Thus, 
a longitudinal study is needed to better understand the predictors of short and long-term 
adherence and to explore ways to better assess the relevance, content and quality of social 
support services being utilized by ART patients at facility and community levels.   
 
 Additionally, appropriate interventions and polices are needed to respond to the 
concerns identified from the study regarding inability to attend to the problems of patients 
because staff are too busy, and the perception that staff do not treat patients with enough 
respect. Other concerns requiring action include patients leaving without receiving 
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treatment, absence or lateness of doctors and pharmacists and challenges around access to 
food, income and disability grants.  
 
 Finally, it is important that funding agencies and government at all levels support 
the implementation of comprehensive social support services, that are capable of promoting 
adherence, and facilitate research activities to study adherence, qualitatively and 
quantitatively over time, rather than the current focus on supplying basic kits, materials, 
training and medications for ART rollout in South Africa.   
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Appendix 1. Ethics Committee Letter 
 
UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG 
Division of the Deputy Registrar (Academic & Research) 
 
MEMORANDUM 
 
TO:  Dr EE Williams 
  School of Public Health 
  Sent by e-mail ewilliams@pcjoburg.org.za     
 
FROM: Ms Anisa Keshav 
  Secretary: Human Research Ethics Committee (Medical) 
  Tel 717-1234 fax 339-5708 e-mail keshava@research.wits.ac.za 
 
DATE:  2 December 2005 
 
REF:  R14/49 
 
Protocol M051101: A Study of Social Support an Art Adherence at Two Sites in Gauteng 
Province 
 
The above protocol was considered at a meeting of the Human Research Ethics 
Committee(Medical) on Friday 25 November 2005.  The Committee requires the following 
amendments/corrections/information from you before your application can be approved.  
 
-The consent form must be revised to be more user friendly and include a greeting, 
an invitation to participate etc 
-Separate consent signatures needed for tape recording and the fate of the tapes 
must be stated 
-Please clarify- how will individuals be contacted? 
-Remove DOB as this is loss of confidentiality 
 
Please let me have the amendments as soon as possible as protocols on which no action has 
been taken will be removed from the agenda without approval after two months. 
 
Cc  
 
NB: please highlight the changes you submit 
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Appendix 2: Data Collection Domains 
 
   Domain Indicator(s) Method 
Background 
information 
• Demographic profile age, 
sex, 
• Socio-econ profile e.g. 
Location, medical aid, 
assets owned, grants, 
employment, education 
level 
 
• Review of ART 
register  
• Exit interview 
Continuity of care  
 
Pathways of care e.g. 
• Entry  
• Referrals 
• Preparation 
• Aids and reminders 
(locus of ctrl ->self Mx)  
 
• Review of TB 
register 
• Presence of 
networking and 
referral 
relationships 
• Exit interview 
Social support 
 
• Links to NGO’s 
• Needs? 
• Disclosure and acceptance 
• Family support 
• Alternative therapy e.g. 
trad. Healing 
• Counseling 
• Semi-Structured 
interview schedule 
• Presence of 
networking 
relationships 
Knowledge and 
treatment literacy 
• Identification of 
medicines 
• Number of regimens 
• Definition of HIV/AIDS 
and transmission 
• Definitions of anti retro-
virals and dosages and 
side effects 
• Semi-Structured 
interview schedule 
• Exit interview 
 
Patient provider 
relation ship-Quality 
of relationship 
• Type of staff attending to 
patient e.g. nurse doctor 
• Language barriers 
• Perception of attitude of 
staff e.g. rude, courteous 
etc 
• Advice about regimens  
• Type of information 
provided e.g. leaflets, 
posters 
•  
• Semi-Structured 
interview schedule 
• Exit interview 
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Adherence • Patient self reported 
adherence rates,  
• Viral load suppression,  
• Patient follow-up rates 
• Review of patient 
clinical records,  
• Review of 
information 
systems for 
monitoring of 
patients 
and  Physical 
barriers to adherence 
• Costs –indirect (transport 
and food, 
accommodation) 
• Direct (Rx related)-cost of 
regimens etc 
• Proportion of doses 
missed in last 2days, 1 
week and 2weeks 
• Side effects 
• Clinic visits per capita and 
missed visits 
 
• Exit interview 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71
Appendix 3: Exit Interview Questionnaire  
 
ARV Adherence Questionnaire 
 
CONSENT 
 
INTERVIEWER INTRODUCES HIM/HERSELF, AND THE STUDY, AND THEN…. 
I would like to ask you questions to ensure that the information I have provided so far is clear, and give you 
the opportunity ask any question(s) you have.  
 
NO QUESTION RESPONSE CODES 
1.  Do you understand the purpose of the study, and what will be required of 
you if you agree to take part? 
 Yes=1 
No=0 
2.  If no, what further questions what further questions do you wish?  
3.  Do you understand that any time you may withdraw from this study 
without giving a reason? 
 
4.  Do you understand that this study is in no way linked to the organizations 
that provide care, and withdrawing or participating will not affect the care 
that you receive? 
 
5.  Do you agree to take part in this study?  
Written consent 
I agree to participate in this study, having understood and answered yes to all of the above questions. 
Initials of respondent:  
                                              …………………………………………………………………….. 
Verbal consent 
As the respondent is illiterate, or is happy to provide verbal but not written consent, I, the field worker, confirm that 
the respondent gave verbal consent to be interviewed. 
Signature of interviewer:  
                                               ……………………………………………………………………. 
INTERVIEW DETAILS 
 
NO QUESTION RESPONSE CODES SKIP
6.  Clinic patient number (8 digits + 2 letters) 
  
7.  
Facility name  Carltonville = 1 
Zola = 2 
Empilisweni = 3 
Natalspruit = 4 
 
8.  Date of interview  
D D M M Y Y Y Y   
9.  
Name of interviewer  Interviewer names =1 
=2  
=3 
=4 
 
Signature of researcher that has 
checked questionnaire 
   
10.  Questionnaire number 
ONLY TO BE COMPLETED ONCE QUESTIONNAIRE HAS BEEN 
CHECKED, AND IS COMPLETE 
    
 72
SECTION 1: SOCIO-DEMOGRAPHIC BACKGROUND 
 
I would like to ask you a few questions about yourself. We are asking these questions of everybody 
participating in this study. Feel free to stop me if you have any questions.
No. QUESTIONS  RESPONSES CODES SKIP 
11.  GENDER  Male =01; 
Female=02 
 
12.  What is your date of birth? 
WRITE AGE IF DATE NOT KNOWN 
D D M M Y Y Y Y   
13.  What is the highest educational level that 
you have COMPLETED? 
 
 No formal education =0 
Grade 1/SubA=1 
Grade 2/Sub B=2 
Grade 3/Standard 1 =3 
Grade 4/Standard 2/ABET L1 =4 
Grade 5/Standard 3=5 
Grade 6/Standard 4/ABET L2=6 
Grade 7/Standard 5 =7 
Grade 8/Standard 6/ABET L3 = 8 
Grade 9/Standard 7 = 9 
Grade 10/Standard 8/ABET L4 = 10 
Grade 11/Standard 9 = 11 
Grade 12/Standard 10/ABET L5 = 
12 
Diploma = 13 
Degree = 14 
Other: Specify------------------ 99 
 
 
14.  Have you done any activity to earn money in the past two weeks? IF 
NO, 
>Q17 
15.  IF YES: Can you describe the type of work you have been doing, including how often you do 
this work? 
PLEASE WRITE EXPLANATION 
 
 
 
 
 
16.  IF WORKING: How would you best describe the work that 
you do? 
 Full time =1 
Self-employed = 2 
Casual or part-
time work  = 3 
 
17.  Do you currently receive a disability grant?  Yes=1 
No=0 
IF 
YES 
>Q19 
18.  IF NO:  Have you applied for one?  Yes=1 
No=0 
 
 
 
I’d like to now ask you about your costs coming here today  
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 ITEM COST PER VISIT Codes 
19.  How much did it cost you to travel to and from 
the hospital/clinic (the return trip)? 
R Don’t 
know = -1 
 
PUT 
ZERO IF 
SPENT 
NO 
MONEY 
ON ITEM 
 
20.  Subsistence (food) during visit? R 
21.  Medication received at hospital/clinic? R 
22.  Consultation at hospital/clinic? R 
23.  Accommodation (if needed to stay over) during 
visit? 
R 
24.  Are there any other COSTS that I have not 
mentioned? 
 Yes =1 
No = 0 
25.  IF YES: What else did you spend money on, and how much? 
26.  At present, do you have a medical aid?   Yes =1 
No=0 
 
27.  DID THE PERSON SAY THEY HAVE BEEN WORKING 
IN THE PAST TWO WEEKS? CHECK Q15 
 Yes =1 
No = 0 
IF NO, 
> Q31 
28.  IF YES, Did you miss work by coming here?   Yes =1 
No = 0 
IF NO, 
> Q31 
29.  IF YES: Did you loose salary or income by coming here?  Yes =1 
No = 0 
IF NO, 
> Q31 
30.  IF YES, How much income do you lose per visit? 
    
 
R____________per 
visit 
 
31.  What is the main source of drinking water for 
members of your household? 
READ OUT EACH OPTION 
 
Other: 
Specify…………………………………………… 
 
 
 Rain water /tank = 1 
Borehole/well = 2 
Water carrier/tanker = 3 
Public tap = 4 
Piped water (tap) in site, 
yard = 5 
Piped water (tap) in 
dwelling = 6 
Bottled water = 7 
Other = 99 
 
32.  What kind of toilet facility does your household 
have? 
READ OUT EACH OPTION 
 
Other: Specify…………………………………………. 
 
 Flush toilet (own)=5 
Flush toilet (shared) = 4 
Bucket latrine = 3 
Pit latrine=2 
No facility/bush or veld = 
1 
Other=99 
 
 
33.  What type of home do you live in? 
READ OUT EACH OPTION 
 
Other: Specify…………………………………………. 
 
 Shack / informal dwelling 
in back yard=1 
Shack / informal dwelling 
=2 
Hostel =3 
 
 74
House/flat/Room in back 
yard=4 
Room/flatlet not in back 
yard but on shared 
property=5 
Flat in a block of flats = 6 
Formal house = 7 
Other = 99 
34.  What is the main material of your house’s floor? 
READ OUT EACH OPTION 
 
 
Other: Specify…………………………………………. 
 
 Earth / sand / dung = 1 
Bare wood planks = 2 
Cement = 3 
Vinyl or plastic = 4 
Carpet/ tiles/ polished 
wood = 5 
Other = 99 
 
35.  What is the main material of your house’s wall? 
READ OUT EACH OPTION 
 
Other: Specify…………………………………………. 
 
 Plastic / cardboard = 1 
Mud = 2 
Mud and cement = 3 
Corrugated iron / zinc = 4 
Bare brick / cement blocks 
= 5 
Plaster / finished = 7 
Other = 99 
 
36.  Do you have electricity in your household?   Yes=1 
No = 0 
 
Can you tell me if you household has any of the following appliances, that are working?  
37.  Television  Yes=1 
No = 0 
 
38.  Telephone (land line)  
39.  Fridge  
40.  Personal computer  
41.  Washing machine  
42.  Radio  
43.  Cell-phone  
44.  What does your household use mainly for cooking? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity 
=6 
Gas = 5 
Paraffin = 
4 
Wood = 3 
Coal = 2 
Animal 
dung=1 
Other = 99 
 
45.  What does your household use mainly for heating? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity 
=6 
Gas = 5 
Paraffin = 
4 
Wood = 3 
Coal = 2 
Animal 
dung=1 
Nothing=7 
Other = 99 
 
46.  What does your household use mainly for lighting? 
READ OUT EACH OPTION 
 
If other, specify……………………………… 
 Electricity 
=6 
Gas = 5 
Paraffin = 
Coal = 2 
Animal 
dung=1 
Other = 99 
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4 
Wood = 3 
Does any member of your household own any of the following?  
47.  A bicycle  Yes=1 
No = 0 
 
48.  A motorbike  
49.  A car  
50.  A donkey or horse  
51.  Sheep or cattle  
52.  Would you say that the people at home often, 
sometimes, seldom or never go hungry? 
 Often = 1 
Sometimes = 
2 
Seldom = 3 
Never = 4 
 
53.  Do you receive food supplement/food parcel from any 
source?  
 Yes = 1, No 
=0 
 
 
SECTION 2: KNOWLEDGE OF HIV/AIDS AND ARVs 
 
I would now like to ask you some questions about AIDS and ARVS 
NO QUESTION RESPONSE CODES SKIP 
54.  Can you tell me about ARVs, what do they do?  
WRITE RESPONSE 
 
 
 Correct 
response=1 
Incorrect 
response =0 
Don’t know = -
1 
 
I am going to read you some statements. I would like you to tell me, for each one, whether you 
think the statement is True or False, or you don’t know 
 
55.  People receiving ARVs can still transmit HIV to other people 
through unprotected sex. 
 True = 1 
False = 0 
Don’t 
know = -1 
56.  It is acceptable to stop ARVs after gaining weight  
57.  It is acceptable to stop ARVs when one no longer suffers from 
opportunistic infections 
 
58.  ARVs cure HIV/AIDS.  
59.  After a couple of years one can stop taking ARVs.  
60.  Missing a few tablets of ARVs is acceptable.  
61.  Unprotected sex is safe when one is taking ARVs  
 
 
SECTION 3: CONTINUITY OF CARE 
 
I will like to obtain some information from you about when you were diagnosed with HIV or AIDS and 
where and how you have received treatment and care. 
NO QUESTION RESPONSE CODES SKIP 
62.  When did you first test positive for HIV?  
 
D D M M Y Y Y Y Don’t know = 
-1 
 
At which health care facility (clinic or hospital) did you FIRST test HIV positive?    
63.   
Name of clinic or hospital:………………………………………. 
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64.  FILL IN IF YOU KNOW 
Town / City:……………………………………….. 
 
65.   
Province:  
 Gauteng = 1 
Mpumalanga = 2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape = 7 
N. Cape = 8 
KZN=9 
Where did you FIRST seek treatment after you were FIRST diagnosed with AIDS?  
66.   
Name of clinic or hospital:………………………………………. 
 
67.   
Town / City:……………………………………….. 
 
68.   
Province:  
 Gauteng = 1 
Mpumalanga = 2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape = 7 
N. Cape = 8 
KZN=9 
69.  When did you FIRST begin taking ARVs?  
 
D D M M Y Y Y Y Don’t know = 
-1 
 
70.  Have you received ARVs from a clinic / service other than this one?   Yes = 1; 
No = 0 
IF 
NO, 
>Q74 
Can you tell me the name of the clinic / hospital, which town/city AND province?  
71.   
Facility name:……………………………………………… 
 
72.   
Town / city: ………………………………………………. 
 
73.   
Province 
 Gauteng = 1 
Mpumalanga = 2  
Limpopo = 3 
North West = 4 
Free state = 5 
E. Cape = 6 
W. Cape = 7 
N. Cape = 8 
KZN=9 
 
 
SECTION 4: ADHERENCE 
 
I would like to ask you some questions about how you are coping with taking the ARVs regularly. We want 
to understand better the real life challenges that people on ARVs face in taking their pills. 
 
NO QUESTION RESPONSE CODES SKIP 
74.  Can you tell me the name of each of your drugs?  
(WITHOUT LOOKING AT THE CONTAINER)  
 
 Yes = 1 
No = 0 
IF 
YES 
>Q76
75.  IF NO: Can you point to the pictures of each of your 
drugs?  
OR PERSON READS THE NAMES FROM THE 
CONTAINERS 
 
WRITE IN ALL DRUG NAMES BELOW FIRST AND 
THEN GO BACK ASK QUESTIONS ABOUT EACH 
ONE? 
 Yes = 1 
No = 0 
 
76.  DRUG 1: WRITE DRUG NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
77.  How many times a day to do you take ……. (drug)?    
78.  How many tablets of …… (drug) do you take in one day?    
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79.  DRUG 2: WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
80.  How many times a day to do you take …… (drug)?    
81.  How many tablets of ……. (drug) do you take in one day?    
82.  DRUG 3; WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
83.  How many times a day to do you take ….. (drug)?    
84.  How many tablets of ….. (drug) do you take in one day?    
85.  DRUG 4: WRITE NAME GIVEN, CHECK SPELLING ON LIST 
 
 
 
86.  How many times a day to do you take …… (drug)?    
87.  How many tablets of …. (drug) do you take in one day?    
 
People may miss taking their ARVs for various reasons. What, in your experience, are the main reasons why 
people miss their tablets? WRITE RESPONSES, PROMPT FOR MORE THAN ONE REASON  
88.  Reason 1:  
 
 
  
89.  Reason 2: 
 
 
 
90.  Reason 3 
 
 
 
For each of drugs, can you tell me how many tablets, if any, you missed YESTERDAY?    
WRITE IN DRUG NAMES FROM ABOVE 
 
 NAME OF DRUG Number of 
tablets missed
Reason for 
missing 
 
91.  Drug 1    
92.  Drug 2    
93.  Drug 3    
94.  Drug 4    
For each drug, can you tell me how many tablets, if any, you missed THE DAY BEFORE 
YESTERDAY (INDICATE WHICH DAY YOU ARE REFERRING TO - MON, TUE ETC.)?   WRITE 
IN DRUG NAMES  
 NAME OF DRUG Number of 
tablets missed
Reason for 
missing 
 
95.  Drug 1    
96.  Drug 2    
97.  Drug 3    
98.  Drug 4    
For each drug, can you tell me how many tablets, if any, you missed 3 DAYS AGO?   (INDICATE 
WHICH DAY YOU ARE REFERRING TO - MON, TUE ETC.)?   WRITE IN DRUG NAMES  
 NAME OF DRUG Number of 
tablets missed 
Reason for 
missing 
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99.  Drug 1    
100. Drug 2    
101. Drug 3    
102. Drug 4    
103. If you didn’t miss any tablets in the 
last three days, when was the last time 
you missed any of your medications? 
 Within the last:  
Week =1 
2 weeks = 2 
3 months = 3 
More than 3 
months ago = 
4  
Never missed 
= 5 
104. IF EVER MISSED TABLETS: 
What is the longest time you have ever missed your tablets? 
 INDICATE 
DAYS OR 
MONTHS 
 
 
 
105. Do you belong to a support group?  Yes=1,  
No= 0 
If NO, 
>Q115
106. IF YES: How often do you attend?  Weekly = 1 
Monthly = 2 
Occasionally 
=3 
 
IF YES, What services are offered at the support group? 
READ OUT EACH OPTION 
 
107. Advice and information on staying healthy e.g. nutrition, 
exercise and prevention 
 Yes=1,  
No= 0 
108. ARV information: CD4 counts, ARVs, viral load  
109. Treatment buddies  
110. Help with collecting medicines from the clinic  
111. Home visits  
112. Food  
113. Income generating activities  
114. Individual counselling and emotional support    
Do you receive any of the following help or support from your friends or family to help you take your tablets 
regularly? 
READ OUT EACH OPTION 
115. They visit you  Yes=1,  
No= 0 
 
116. They send an sms or call you by phone  
117. They give you food to take your pills with  
118. They provide transport money to the clinic  
119. They provide emotional support  
120. Is there any other type of help that you receive? 
 
Specify:………………………………………… 
 
121. Are there people interested in buying ARVs?  Yes =1, No=0 
Don’t know = -
1 
 
122. Do you know of people who have sold their ARVs?   
123. Has there ever been a month when you couldn’t come to clinic 
for your monthly visit? 
 Yes =1 
No=0 
IF NO 
>135 
124. IF YES, how many times did you miss coming in the last 6 
months, since _____ (MONTH)? 
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IF YES, What was the reason for skipping the appointment?  
READ OUT EACH OPTION 
 
125. You were working  Yes =1 
No=0 
Not relevant - 
2 
 
126. You were sick  
127. You forgot  
128. You mixed up the dates  
129. You were away out of town  
130. You had no transport money  
131. You had nobody to look after the children  
132. You were afraid that somebody would see you and judge you 
negatively 
 
133. You were afraid that your partner would find out and ask me to 
explain 
 
134. Is there any other reason that made you miss your visit? 
 
Specify reason:………………………………………….. 
 
135. Can you tell me in your own words what a CD4 count is? 
WRITE DOWN WORDS HERE: 
 
 
 
 
136. Can you tell me what your most recent CD4 count is?  Write in number 
given, OR, Don’t 
know = -1 
 
137. When are you due for your next CD4 count?  MONTH AND 
YEAR 
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SECTION 5: QUALITY OF CARE/PATIENT PROVIDER RELATIONSHIP 
I would now like to know about your experiences when at this clinic and how the health providers interact 
with you. 
138. Are you able to talk to the health workers in private?   Yes = 1, No = 0 If 
YES 
>Q140
139. IF NO, does it bother you?    Yes =1, No=0  
140. How many hours do you spend at the clinic at each visit?  INDICATE 
HOURS 
 
I am going to read some statements about your meeting with the health workers today. Can you tell me 
whether you agree or disagree with these statements? 
IF THE PERSON CAN’T DECIDE CHOOSE NO VIEW/DON’T KNOW 
141. The queues to be seen by a doctor or nurse are too long at this 
facility 
 Agree=1 
Disagree=2 
Agree and 
disagree=3 
No view/don’t 
know=4 
Not relevant= -2 
 
142. The health worker DID’NT discuss the treatment fully with 
you, including how the treatment works and side effects.  
 
143. It is a problem that the health worker DOESN’T speak your 
language 
 
144. You find it difficult to tell the health worker when you have 
missed taking your tablets 
 
145. You would not tell him/her because s/he would shout at you.  
146. The health worker was too busy to listen to your problems   
147. The health worker provided you with feedback on whether the 
drugs were working or not 
 
148. The health worker understood the difficulty of taking the drugs 
and assisted you where possible 
 
149. Some staff DO NOT treat patients with sufficient respect.   
150. When I need to obtain other care that they cannot provide in 
this clinic, I was given enough help to get to the right place 
 
151. The health workers I see care about me.  
152. Since enrolling at this clinic/hospital, have you ever left without 
being helped  
 
 
Yes=1 
No=0 
IF NO 
>Q154
153. IF YES, why did you leave without being helped? 
WRITE FULL EXPLANATION:  
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SECTION 6: SOCIAL SUPPORT AND ACCEPTANCE 
 
I would like you to tell me about the support your receive to help you cope with your HIV status and to take 
your ARVs. 
154. Apart from the health workers, have you told anyone about 
your HIV status? 
 Yes =1 
No= 0 
If NO,  
> Q162 
IF YES, whom of the following have you told about your HIV status?  READ OUT EACH OPTION  
 155. Spouse / partner, if you have one  Yes =1 
No= 0 
If no spouse = -
2 
Yes = 1, No = 0 
Don’t know =-1 
156. Family member  
157. Friend  
158. Neighbour  
159. Religious leader   
160. No-one  
161. Is there another category of person to whom you have told your 
status we have not already mentioned?   
 
Other (specify)------------------ 
 
162. Has your HIV status been disclosed to other people without 
your permission? 
 
 
Yes=1 
No=0 
Do you keep your status secret for any of the following reasons:  
READ OUT EACH OPTION 
163. Fear of rejection by family  Yes =1 
No= 0 
 
 
164. Fear of rejection by friends  
165. Fear of violence  
166. I do not trust people   
167. I will not get help from others if they know my status  
168. Fear that I will be stigmatised   
169. Fear that people will gossip about me  
170. Fear that HIV my status will be known by the community  
171. Fear that my partner will know and ask me to explain  
172. Is there any other reason? 
 
Specify …………………………………………… 
 
 
I would like to ask you how supportive your family, friends and colleagues are towards you.  
173. How would you describe your partner’s behaviour towards 
you, if you have a partner – supportive or unsupportive? 
 Supportive=1  
Unsupportive=2 
Both supportive 
and 
unsupportive=3 
Not relevant=4 
 
174. How would you describe the behaviour of your family towards 
you? 
 
175. How would you describe the behaviour of your friends towards 
you? 
 
176. How would you describe the behaviour of the people you live 
with towards you? 
 
177. How would describe the behaviour of your work colleagues 
towards you? 
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SECTION 7: FOLLOW-UP  
We are planning to do a more detailed study, visiting a few patients in 
their homes to find out more about how they are coping the HIV and 
the treatment. Would you be willing to be part of that study?  
IF YES, WRITE NAME AND TEL NO ON SEPARATE PIECE OF 
PAPER 
 Yes=1 
No = 0 
 
 
 
THAT IS THE END OF THE INTERVIEW DO YOU HAVE ANY QUESTIONS YOU 
WANT TO ASK ME? 
 
DO YOU WANT TO ADD ANYTHING? WRITE IN SPACE BELOW OR ON BACK OF 
QUESTIONNAIRE 
 
 
 
 
 
MANY THANKS FOR YOUR HELP – WE REALLY APPRECIATE IT! 
 
 
INTEVIEWER: PLEASE COMPLETE THESE QUESTIONS IMMEDIATELY AFTER THE 
INTERVIEW. 
 
 
178. INTERVIEWER: How clear was the meaning of the respondent’s 
answers 
 Good = 1 
Average =2 
Poor = 3 
 
179. INTERVIEWER: How attentive was the respondent to the 
questions during the interview? 
 Good = 1 
Average =2 
Poor = 3 
 
180. INTERVIEWER: What was your impression about this person’s 
willingness to talk in more detail about their illness and how they 
are coping with it? 
 Willing = 1 
Doubtful = 2 
Unwilling = 3 
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Appendix 4a: Letter of Request from Centre for Health Policy 
 
 
 
 
 
 
 
 
 
 
7 April 2006 
 
Dr A Victor 
Acting Director 
West Rand District 
Gauteng Department of Health 
Dear Dr Victor 
MPH student projects 
In discussions between the SPH and Head Office, a number of projects for MPH students 
were identified, one of which involves a facility in your district. The project is an analysis 
of adherence and associated facility and patient factors in one ARV/CCMT sites.  In a 
random selection process we identified the Carletonville Hospital site, and we would like 
your permission to approach the facility. Alternatively, if you are of the opinion that this 
site is inappropriate given its relocation to the North-West we can discuss another site in 
your district. The project team will involve two MPH students and staff in CHP. HAST 
(Head Office) gave its approval for this and notified the individual sites at the end of 2005.   
 
Attached find the following: 
1) A letter of approval from head office with a list of all the MPH students and their 
projects in the province as a whole (to give you a sense of the range) 
2) A summary of the project 
3) A copy of the letter sent by HAST 
 
I believe Dr Mazizi has forwarded a letter of approval from his office. 
  
The topics of the projects were identified by the Department of Health and have been 
approved by both the Higher Degrees and the Ethics Committees of the University.  
 
I trust that this request is in order and we hope that these activities will provide the 
opportunity for identifying what are your priorities for future evaluations in your district. 
 
Many thanks  
 
Helen Schneider (Prof) 
Cc: Ms Nomsa Makwela 
 
 
 
 
Centre for Health Policy, School of Public Health 
UNIVERSITY OF THE WITWATERSRAND,  JOHANNESBURG
NHLS cor. De Korte & Hospital Streets 
Braamfontein, Johannesburg 
 PO Box 1038 Johannesburg 
 2000 South Africa 
  (011) 242-9905 
Fax (011) 720-0010 
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Appendix 4b:  Letter of Introduction  
 
 
 
 
    HAST (HIV/AIDS / STI / TB) 
 
       Enquiries: Dr R.N. Dlamini: 
Technical Advisor:            Tel:  
011 355-3383 
       Fax: 011 355-3297 
       Date: 19 November 2005 
      
To : Natalspruit Hospital: ART Project Manager: Sr JZ Buthelezi 
  Carltonville Hospital: ART Project Manager: Sr Motseko / Ms 
Musi 
  Empilisweni CHC: ART Project Manager: Sr Nthombi 
Mokgatla 
  Zola CHC: ART Project Manager: Sr P. George /  Makeda 
 
  HAST Project Managers  
Cc : Dr D. Moloi: Director: HAST 
  Dr N. Ntzebeza: PMO – Ekurhuleni  
  Dr M. Shisana: PMO – Joburg Metro  
  Dr B. Ribiero: PMO – Tswane / Metsweding  
  Dr F. Bosama: PMO – Central Provincial Office  
  Ms N. Mfecane: Project Manager: ARV (CCMT)   
 
From  :  Dr R.N. Dlamini: Technical Advisor: HAST    
Re  :  Wits School of Public Health Students Projects   
 
HAST works in very close collaboration with the Wits School of Public 
Health.  Their MPH students are involved in operational research that will 
provide useful information in the way we run and manage our 
Comprehensive Care Management and Treatment clinics (CCMT). 
The research topics and protocols have all been submitted to HAST and to 
the Research Unit at Central office. HAST therefore requests that the 
students are given access to the CCMT clinics to conduct the various 
research projects. 
 
Thank you 
________________ 
 Dr R.N. Dlamini: Technical Advisor: HAST    
 
Appendix 5:  
Data Analysis 
PlanStudy 
Objectives 
 
Indicators (s) Source and Means of 
verification 
Level of Data 
Collection 
Department of Health 
Lefapha la Maphelo 
Departement van Gesondheid 
Umnyango wezeMpilo 
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1. Investigate what 
social support 
services patients are 
using and how 
these services are 
meeting their needs. 
 
 *Questions relating to disclosure (Q 
154-172) 
*Questions relating to support from 
family etc (Q 173-177) 
* Questions relating to support from 
health workers 
- Exit interview 
 
- In-depth interviews 
 
- Routine data 
 -ART patients  
 
- Facility 
managers 
2. Determine 
adherence levels 
among ART 
patients. 
*Questions related to missed taking 
tablets (Q 91-104) 
*Questions related to follow-up 
visits (Q 123 –143) 
* Viral load count 
- Exit interview 
 
- Data capture sheets  
-ART patients 
 
-Clinic record 
3. What are the 
factors affecting 
adherence? 
*Questions relating to cost of 
attending clinic and income lost  
(Q 19-30) 
* Questions relating to knowledge 
about drugs (Q74-87) 
*Questions relating to participation 
in support groups (Q 105, 106) 
*Questions relating to services 
offered in support groups (Q 107-
114) 
*Questions relating to support from 
family friends, etc (Q. 115-120) 
* Questions relating to knowledge 
about CD4 count. (Q135-137) 
*Questions relating to quality of 
care) Q138-152)  
- Exit interview 
 
- In-depth interviews 
 
- Routine data 
-ART patients 
 
- Facility 
managers 
4. Examine the 
association between 
social support and 
adherence 
* Cross tab social support and 
adherence  
- Exit interview -ART patients 
5. Socio-
demographic 
background of 
patients  
*Questions relating to background 
(Q 11-18) 
- Exit interview -ART patients 
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Appendix 6: Respondents’ File Data Capture Sheet 
 
 
Name of Hospital/Clinic:  Carletonville Hospital  -------- 
 
           Zola Clinic  --------- 
 
 
Client File Number  
 
 
Date   
 
(Day/Month/Year) 
 
File Record:  
 
Type of Data 
 
Information Required 
Start date for ART treatment  
Date stopped treatment (if 
applicable) 
 
Total visits scheduled  
( April 2005 and March 2006) 
 
Actual Number of visits made 
during this period 
 
Last viral load count Date of current 
test 
CD4 count  Next scheduled 
test 
   
Last CD4 cell count Date of current 
test  
CD4 count  Next scheduled 
test 
   
Screening for TB Date of screening Result: Neg/Pos Treated for TB 
(Yes/No) 
   
   
 
 
 
 
 
 
 
 
 
 
Appendix 7: Social Support and Adherence: Research Report FrameworkSocial Support 
and Adherence 
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Study Objectives  Section Highlights Results Tables  
Determine what types of support 
services are available at facility 
and community levels for ART 
adherence in the sites of the 
study 
 
(Here I am interested in 
describing the types of services 
and support ART clients can get 
when they come to the clinic and 
have access to at the community 
level from family members, 
friends, or colleagues. This will 
not include their use of these 
services, but a focus on how 
comprehensive these are. 
I can think of social support 
broadly as anything, which 
empowers patients to understand, 
cope and facilitate adherence. This 
could relate to support gained 
through relationships, 
networks/organizations/institutions; 
skills and information; resources 
etc. Therefore we can think of the 
following areas where respondents 
could derive social support: 
Education 
Access to grants 
Food supplement 
Medical aid 
Employment 
Support group membership  
Types of support provided by 
health providers 
HIV and ART knowledge 
Assets 
a) Socio-demographic results:  
Age group 
Gender 
Educ. level 
Assets quintiles 
b) Financial and material support: 
Disability grant 
Food supplement 
Income/employment 
c) Health Facility support 
Areas of interactions with health 
providers 
Content of interactions 
d) Community Support 
 Support groups 
Support from friends, family 
colleagues 
e) Adherence 
incentives/disincentives: 
Disclosure 
Stigma issues 
Reasons why people do not take 
tablets  
Clinic attendance and reasons 
why people do not attend clinic 
Investigate what social support 
services patients are using and 
how these services are meeting 
their needs 
 
Here I am interested in assessing  
how the available social support 
services are being used, 
proportions of respondents using 
services, commonly used services 
vs. those that are less used, and 
how relevant these might be to 
their needs.  
I could quantify the proportions of 
the use of services by respondents 
and compare use by gender. Also, 
would explore service used by age 
group. Main analyses areas are: 
Examine the different types of 
services reported by support group 
members and the frequency of their 
use, including by gender. 
Examine what support service 
health providers offer and 
perceptions about these services.  
 Examine the types of support 
services provided by family 
members and friends, and assess 
their comparative frequencies. 
Examine services that are 
missing/poorly delivered/utilized 
 
Results to be discussed will 
include: 
Support group membership and 
attendance 
Services provided by support 
groups, and proportion of users 
Support services provided by 
family and friends 
Disclosure and concerns about 
disclosure  
Provider/client interactions 
Determine adherence levels 
among ART patients and 
examine the association between 
social support and adherence 
 
Focusing on VL count below and 
above 400 copies/ml, adherence 
levels will be determined for all 
respondents with VL information. I 
will also provide VL levels by site, 
Results to be highlighted will 
include: 
Self-reported adherence, CD4 
count and VL counts 
Cross tabs between VL and key 
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Will  focus on VL and CD4 
counts as main measure of 
adherence. Will compare a range 
of social support variables to 
measure correlation between 
adherence and social support.  
and by gender. Will provide levels 
for respondents based on their 
duration on treatment. Areas o 
focus will include: 
 
Concerns around SRA and CD4 
count as measure of adherence 
VL as measure of adherence 
Social support variables linked to 
adherence 
 
 
social support indicators  
 
 
 
 
 
 
 
 
 
